| Year |
Citation |
Score |
| 2023 |
Russell PA, Farrall AL, Prabhakaran S, Asadi K, Barrett W, Cooper C, Cooper W, Cotton S, Duhig E, Egan M, Fox S, Godbolt D, Gupta S, Hassan A, Leslie C, et al. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study. Pathology. PMID 37833206 DOI: 10.1016/j.pathol.2023.08.008 |
0.626 |
|
| 2023 |
Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, ... ... Fox SB, et al. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group. The Journal of Pathology. PMID 37608772 DOI: 10.1002/path.6155 |
0.337 |
|
| 2023 |
Takano EA, Younes MM, Meehan K, Spalding L, Yan M, Allan P, Fox SB, Redfern A, Clouston D, Giles GG, Christie EL, Anderson RL, Zethoven M, Phillips KA, Gorringe K, et al. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival. Bmc Cancer. 23: 459. PMID 37208678 DOI: 10.1186/s12885-023-10795-5 |
0.365 |
|
| 2023 |
Deb S, Chakrabarti A, Fox SB. Prognostic and Predictive Biomarkers in Familial Breast Cancer. Cancers. 15. PMID 36831687 DOI: 10.3390/cancers15041346 |
0.332 |
|
| 2022 |
Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, ... ... Fox S, et al. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. European Journal of Cancer (Oxford, England : 1990). 173: 178-193. PMID 35933885 DOI: 10.1016/j.ejca.2022.06.011 |
0.317 |
|
| 2022 |
van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, Kuykhoven KS, Caramia F, Salgado R, Francis PA, Dawson SJ, Fox SB, Fellowes A, Loi S. Correction to: Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research : Bcr. 24: 50. PMID 35841108 DOI: 10.1186/s13058-022-01539-7 |
0.307 |
|
| 2022 |
Doig KD, Fellowes A, Scott P, Fox SB. Tumour mutational burden: an overview for pathologists. Pathology. PMID 35153070 DOI: 10.1016/j.pathol.2021.11.008 |
0.773 |
|
| 2021 |
Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, ... ... Fox SB, et al. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology. PMID 34937664 DOI: 10.1016/j.pathol.2021.11.002 |
0.549 |
|
| 2021 |
Bouchè V, Aldegheri G, Donofrio CA, Fioravanti A, Roberts-Thomson S, Fox SB, Schettini F, Generali D. BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives? Frontiers in Oncology. 11: 772052. PMID 34804975 DOI: 10.3389/fonc.2021.772052 |
0.484 |
|
| 2021 |
Fox S, Speirs V, Shaaban AM. Male breast cancer: an update. Virchows Archiv : An International Journal of Pathology. PMID 34458944 DOI: 10.1007/s00428-021-03190-7 |
0.349 |
|
| 2020 |
Kalaw E, Lim M, Kutasovic JR, Sokolova A, Taege L, Johnstone K, Bennett J, Saunus JM, Niland C, Ferguson K, Gresshoff I, Bettington M, Pathmanathan N, Tse GM, Papadimos D, ... ... Fox S, et al. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1. British Journal of Cancer. PMID 32939056 DOI: 10.1038/s41416-020-01065-3 |
0.318 |
|
| 2020 |
van Geelen CT, Savas P, Teo ZL, Luen SJ, Weng CF, Ko YA, Kuykhoven KS, Caramia F, Salgado R, Francis PA, Dawson SJ, Fox SB, Fellowes A, Loi S. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Research : Bcr. 22: 91. PMID 32811538 DOI: 10.1186/s13058-020-01328-0 |
0.346 |
|
| 2020 |
Cheasley D, Devereux L, Hughes S, Nickson C, Procopio P, Lee G, Li N, Pridmore V, Elder K, Bruce Mann G, Kader T, Rowley SM, Fox SB, Byrne D, Saunders H, et al. The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. Npj Breast Cancer. 6: 34. PMID 32802943 DOI: 10.1038/s41523-020-00176-7 |
0.358 |
|
| 2020 |
Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, Cappelletti MR, Ciruelos E, Jerusalem G, ... ... Fox SB, et al. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment. PMID 32770287 DOI: 10.1007/s10549-020-05856-3 |
0.766 |
|
| 2020 |
Whittle JR, Vaillant F, Surgenor E, Policheni AN, Giner G, Capaldo BD, Chen HR, Liu HK, Dekkers JF, Sachs N, Clevers H, Fellowes A, Green T, Xu H, Fox SB, et al. Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32245900 DOI: 10.1158/1078-0432.Ccr-19-1872 |
0.346 |
|
| 2020 |
Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, Fox SB, Giudici F, Generali D. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. PMID 32060782 DOI: 10.1007/s10549-020-05565-x |
0.552 |
|
| 2020 |
Hoon Tan P, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt S, Sotiriou C, van Diest P, et al. The 2019 WHO classification of tumours of the breast. Histopathology. PMID 32056259 DOI: 10.1111/his.14091 |
0.313 |
|
| 2019 |
Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, Henderson MA, Nightingale SS, Ho KM, Myles PS, Fox S, Riedel B, Sloan EK. Pre-operative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a Phase II randomized trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31754048 DOI: 10.1158/1078-0432.CCR-19-2641 |
0.308 |
|
| 2019 |
Pavlakis N, Cooper C, John T, Kao S, Klebe S, Lee CK, Leong T, Millward M, O'Byrne K, Russell PA, Solomon B, Cooper WA, Fox S. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology. PMID 31668406 DOI: 10.1016/j.pathol.2019.08.006 |
0.627 |
|
| 2019 |
Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, ... Fox S, et al. Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. Cancer Research. 79: 3008. PMID 31160311 DOI: 10.1158/0008-5472.Can-19-1133 |
0.305 |
|
| 2019 |
Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, et al. Combined tumor sequencing and case/control analyses of RAD51C in breast cancer. Journal of the National Cancer Institute. PMID 30949688 DOI: 10.1093/Jnci/Djz045 |
0.342 |
|
| 2019 |
Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, ... Fox SB, et al. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. The Journal of Pathology. PMID 30843206 DOI: 10.1002/path.5262 |
0.339 |
|
| 2018 |
McCart Reed AE, Kalaw E, Nones K, Bettington M, Lim M, Bennett J, Johnstone K, Kutasovic JR, Saunus JM, Kazakoff S, Xu Q, Wood S, Holmes O, Leonard C, Reid LE, ... ... Fox S, et al. Phenotypic and molecular dissection of Metaplastic Breast Cancer and the prognostic implications. The Journal of Pathology. PMID 30350370 DOI: 10.1002/path.5184 |
0.374 |
|
| 2018 |
Kader T, Hill P, Opeskin K, Goode D, Elder K, Pang J, Fox S, Mann G, Campbell I, Gorringe K. Abstract PD1-12: Identification of copy number alterations associated with the progression of high risk premalignant breast lesions to breast carcinoma Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd1-12 |
0.336 |
|
| 2018 |
Gorringe K, Hughes S, Nickson C, Devereux L, Pridmore V, Rowley S, Byrne D, Cheasley D, Kavanagh A, Mann G, Fox S, Campbell I. Abstract P3-04-06: Genomic analysis of cancers arising in breasts with different mammographic density Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-04-06 |
0.345 |
|
| 2017 |
Pang JB, Molania R, Chand A, Knower K, Takano EA, Byrne DJ, Mikeska T, Millar EKA, Lee CS, O'Toole SA, Clyne C, Gorringe KL, Dobrovic A, Fox SB. LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. Oncotarget. 8: 83626-83636. PMID 29137369 DOI: 10.18632/oncotarget.18886 |
0.409 |
|
| 2017 |
Gorringe KL, Fox SB. Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis. Frontiers in Oncology. 7: 248. PMID 29109942 DOI: 10.3389/fonc.2017.00248 |
0.324 |
|
| 2017 |
Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, et al. Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8: 78870-78881. PMID 29108271 DOI: 10.18632/oncotarget.20239 |
0.813 |
|
| 2017 |
Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB. BRCA2 carriers with male breast cancer show elevated tumour methylation. Bmc Cancer. 17: 641. PMID 28893223 DOI: 10.1186/s12885-017-3632-7 |
0.329 |
|
| 2017 |
Paquet-Fifield S, Roufail S, Zhang YF, Sofian T, Byrne DJ, Coughlin PB, Fox SB, Stacker SA, Achen MG. The fibrinolysis inhibitor α2-antiplasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. Growth Factors (Chur, Switzerland). 1-15. PMID 28697634 DOI: 10.1080/08977194.2017.1349765 |
0.312 |
|
| 2017 |
Byrne DJ, Deb S, Takano EA, Fox SB. GATA3 expression in Triple Negative Breast Cancers. Histopathology. PMID 28211079 DOI: 10.1111/his.13187 |
0.37 |
|
| 2017 |
Jeffreena Miranda P, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, Jochemsen A, Haupt S, et al. MDM4 is a rational target for treating breast cancers with mutant p53. The Journal of Pathology. PMID 28097652 DOI: 10.1002/path.4877 |
0.351 |
|
| 2016 |
Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. PMID 28049579 DOI: 10.1016/j.pathol.2016.10.010 |
0.372 |
|
| 2016 |
Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, Alsop K, Mansour M, Francis PA, Thorne HA, Silva MJ, Kanu N, Dietzen M, Rowan A, Kschischo M, Fox S, et al. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". Plos Medicine. 13: e1002204. PMID 28027312 DOI: 10.1371/journal.pmed.1002204 |
0.311 |
|
| 2016 |
Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. The Lancet. Oncology. PMID 27964843 DOI: 10.1016/S1470-2045(16)30631-3 |
0.383 |
|
| 2016 |
Huo CW, Waltham M, Khoo C, Fox SB, Hill P, Chen S, Chew GL, Price JT, Nguyen CH, Williams ED, Henderson M, Thompson EW, Britt KL. Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis. Breast Cancer Research : Bcr. 18: 106. PMID 27776557 DOI: 10.1186/s13058-016-0767-4 |
0.319 |
|
| 2016 |
Morey AL, Brown B, Farshid G, Fox SB, Francis GD, McCue G, von Neumann-Cosel V, Bilous M. Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. Pathology. PMID 27567228 DOI: 10.1016/j.pathol.2016.05.007 |
0.329 |
|
| 2016 |
Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, ... Fox SB, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. Breast (Edinburgh, Scotland). 29: 55-61. PMID 27428471 DOI: 10.1016/j.breast.2016.07.003 |
0.742 |
|
| 2016 |
Roviello G, Ravelli A, Ida Fiaschi A, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D. Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology & Hepatology. PMID 27376400 DOI: 10.1080/17474124.2016.1209407 |
0.485 |
|
| 2016 |
Roviello G, Ravelli A, Barni S, Petrelli F, Bottini A, Fox SB, Generali D. Is it time for everolimus-based combination in castration-resistant prostate cancer? Future Oncology (London, England). PMID 27250597 DOI: 10.2217/fon-2016-0136 |
0.444 |
|
| 2016 |
Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone CN, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, ... Fox SB, et al. E3 ligase E6AP represses breast cancer metastasis via regulation of ECT2-Rho signalling. Cancer Research. PMID 27231202 DOI: 10.1158/0008-5472.Can-15-1553 |
0.4 |
|
| 2016 |
Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB, Generali D. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer (Oxford, England : 1990). 61: 111-121. PMID 27162152 DOI: 10.1016/j.ejca.2016.04.002 |
0.467 |
|
| 2016 |
Deb S, Lakhani SR, Ottini L, Fox SB. The cancer genetics and pathology of male breast cancer. Histopathology. 68: 110-8. PMID 26768033 DOI: 10.1111/his.12862 |
0.309 |
|
| 2015 |
Huang KT, Mikeska T, Li J, Takano EA, Millar EK, Graham PH, Boyle SE, Campbell IG, Speed TP, Dobrovic A, Fox SB. Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. Bmc Cancer. 15: 669. PMID 26452468 DOI: 10.1186/s12885-015-1676-0 |
0.331 |
|
| 2015 |
Cappelletti MR, Gnetti L, Santini D, Spada D, Fox SB, Generali D. Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? Oncoscience. 2: 567-9. PMID 26244161 DOI: 10.18632/ONCOSCIENCE.168 |
0.497 |
|
| 2015 |
Haupt S, Buckley D, Pang JM, Panimaya J, Paul PJ, Gamell C, Takano EA, Ying Lee Y, Hiddingh S, Rogers TM, Teunisse AF, Herold MJ, Marine JC, Fox SB, Jochemsen A, et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death & Disease. 6: e1821. PMID 26181202 DOI: 10.1038/cddis.2015.173 |
0.377 |
|
| 2015 |
Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Histopathology. PMID 26118394 DOI: 10.1111/his.12765 |
0.543 |
|
| 2015 |
Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, et al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Journal of the National Cancer Institute. Monographs. 2015: 90-6. PMID 26063896 DOI: 10.1093/jncimonographs/lgv023 |
0.622 |
|
| 2015 |
Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, ... ... Fox SB, et al. Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response. Journal of the National Cancer Institute. Monographs. 2015: 64-6. PMID 26063890 DOI: 10.1093/jncimonographs/lgv018 |
0.791 |
|
| 2015 |
Generali D, Fox SB, Cristofanilli M, Bianchini G, Zambelli A, Hatzis C, Barberis M, Tarricone R, Bottini A, Rossi C, Tringali M. Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute. Monographs. 2015: 1-3. PMID 26063875 DOI: 10.1093/jncimonographs/lgv022 |
0.485 |
|
| 2015 |
Takano EA, Hunter SM, Campbell IG, Fox SB. Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. Journal of Clinical Pathology. 68: 362-7. PMID 25713418 DOI: 10.1136/jclinpath-2014-202824 |
0.311 |
|
| 2015 |
Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S, Ferrozzi F, Giardini R, Bertoni R, Turley H, Gatter K, ... ... Fox SB, et al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. British Journal of Cancer. 112: 52-60. PMID 25461806 DOI: 10.1038/bjc.2014.563 |
0.819 |
|
| 2014 |
Kato T, Pezzella F, Steers G, Campo L, Leek RD, Turley H, Kameoka S, Nishikawa T, Harris AL, Gatter KC, Fox S. Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. International Journal of Clinical and Experimental Pathology. 7: 7967-78. PMID 25550840 |
0.819 |
|
| 2014 |
Deb S, Wong SQ, Li J, Do H, Weiss J, Byrne D, Chakrabarti A, Bosma T, Fellowes A, Dobrovic A, Fox SB. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. British Journal of Cancer. 111: 2351-60. PMID 25490678 DOI: 10.1038/bjc.2014.511 |
0.305 |
|
| 2014 |
Trabert B, Falk RT, Figueroa JD, Graubard BI, Garcia-Closas M, Lissowska J, Peplonska B, Fox SD, Brinton LA. Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland. Cancer Causes & Control : Ccc. 25: 1587-93. PMID 25189422 DOI: 10.1007/s10552-014-0461-8 |
0.307 |
|
| 2014 |
Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. British Journal of Cancer. 111: 46-54. PMID 24874483 DOI: 10.1038/bjc.2014.236 |
0.633 |
|
| 2014 |
Bedussi F, Bottini A, Memo M, Fox SB, Sigala S, Generali D. Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall? Expert Opinion On Therapeutic Targets. 18: 665-78. PMID 24833241 DOI: 10.1517/14728222.2014.898064 |
0.588 |
|
| 2014 |
Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, ... ... Fox SB, et al. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". Breast Cancer Research and Treatment. 144: 113-21. PMID 24469643 DOI: 10.1007/s10549-014-2840-y |
0.544 |
|
| 2014 |
Deb S, Johansson I, Byrne D, Nilsson C, Investigators k, Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I, Fox SB. Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 27: 1223-30. PMID 24457463 DOI: 10.1038/Modpathol.2013.231 |
0.33 |
|
| 2014 |
Masoud Rahbari R, Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski J, Verschoor S, KA Miller E, Van der Spek P, Reis-Filho J, Ramsay R, O'Toole S, McNeil C, ... ... Fox S, et al. Enhanced RAD21 Cohesin Expression Confers Poor Prognosis and Resistance to Chemotherapy in High Grade Luminal, Basal, and HER 2 Breast Cancers International Journal of Radiation Oncology*Biology*Physics. 90: S812. DOI: 10.1016/J.IJROBP.2014.05.2343 |
0.358 |
|
| 2013 |
Lai CF, Flach KD, Alexi X, Fox SP, Ottaviani S, Thiruchelvam PT, Kyle FJ, Thomas RS, Launchbury R, Hua H, Callaghan HB, Carroll JS, Charles Coombes R, Zwart W, Buluwela L, et al. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Research. 41: 10228-40. PMID 24049078 DOI: 10.1093/nar/gkt827 |
0.305 |
|
| 2013 |
Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, Gunningham S, Morrin HR, Pellagatti A, Rees MC, Harris AL, Fox SB. The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5740-8. PMID 23969937 DOI: 10.1158/1078-0432.CCR-13-1712 |
0.802 |
|
| 2013 |
Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G. Triple negative breast cancers have a reduced expression of DNA repair genes. Plos One. 8: e66243. PMID 23825533 DOI: 10.1371/journal.pone.0066243 |
0.548 |
|
| 2013 |
Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. British Journal of Cancer. 108: 1587-92. PMID 23579222 DOI: 10.1038/bjc.2013.151 |
0.781 |
|
| 2013 |
Samarajeewa NU, Yang F, Docanto MM, Sakurai M, McNamara KM, Sasano H, Fox SB, Simpson ER, Brown KA. HIF-1α stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. Breast Cancer Research : Bcr. 15: R30. PMID 23566437 DOI: 10.1186/bcr3410 |
0.371 |
|
| 2013 |
McCormack M, Rosa CS, Murphy M, Fox SB. HER2-positive breast cancer metastatic to intracranial meningioma: a case report. Journal of Clinical Pathology. 66: 633-4. PMID 23436926 DOI: 10.1136/jclinpath-2013-201455 |
0.325 |
|
| 2012 |
Deb S, Jene N, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. Bmc Cancer. 12: 510. PMID 23146383 DOI: 10.1186/1471-2407-12-510 |
0.312 |
|
| 2012 |
Karnezis T, Shayan R, Fox S, Achen MG, Stacker SA. The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. Oncotarget. 3: 893-906. PMID 23097685 |
0.344 |
|
| 2012 |
Nguyen BT, Deb S, Fox S, Hill P, Collins M, Chua BH. A prospective pathologic study to define the clinical target volume for partial breast radiation therapy in women with early breast cancer. International Journal of Radiation Oncology, Biology, Physics. 84: 1116-22. PMID 22543203 DOI: 10.1016/j.ijrobp.2012.02.038 |
0.321 |
|
| 2012 |
Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I, McKay MJ, Fox SB. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Research : Bcr. 14: R69. PMID 22537934 DOI: 10.1186/bcr3176 |
0.335 |
|
| 2012 |
Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, ... ... Fox S, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 134-47. PMID 22144499 DOI: 10.1158/1055-9965.Epi-11-0775 |
0.356 |
|
| 2012 |
Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America. 109: 2766-71. PMID 21768359 DOI: 10.1073/pnas.1104778108 |
0.6 |
|
| 2011 |
Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, ... ... Fox S, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 13: R110. PMID 22053997 DOI: 10.1186/Bcr3052 |
0.323 |
|
| 2011 |
Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, ... ... Fox SB, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute. Monographs. 2011: 147-51. PMID 22043063 DOI: 10.1093/jncimonographs/lgr037 |
0.64 |
|
| 2011 |
Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 111-5. PMID 22043055 DOI: 10.1093/jncimonographs/lgr035 |
0.524 |
|
| 2011 |
Generali D, Symmans WF, Berruti A, Fox SB. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 99-102. PMID 22043052 DOI: 10.1093/jncimonographs/lgr030 |
0.554 |
|
| 2011 |
Generali D, Berruti A, Foroni C, Bazzola L, Andreis D, Allevi G, Bersiga A, Dogliotti L, Fox SB, Harris AL, Bottini A. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. Journal of the National Cancer Institute. Monographs. 2011: 67-70. PMID 22043044 DOI: 10.1093/jncimonographs/lgr029 |
0.611 |
|
| 2011 |
Huang KT, Takano EA, Mikeska T, Byrne DJ, Dobrovic A, Fox SB. Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. Breast Cancer Research and Treatment. 130: 319-29. PMID 21755341 DOI: 10.1007/s10549-011-1657-1 |
0.372 |
|
| 2011 |
Yan M, Jene N, Byrne D, Millar EK, O'Toole SA, McNeil CM, Bates GJ, Harris AL, Banham AH, Sutherland RL, Fox SB. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Research : Bcr. 13: R47. PMID 21521526 DOI: 10.1186/bcr2869 |
0.55 |
|
| 2011 |
Shaida N, Chan P, Turley H, Jones CM, Kanga S, Ritchie RW, Malone PR, Harris AL, Fox SB. Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosis. The Journal of Urology. 185: 1513-8. PMID 21334674 DOI: 10.1016/j.juro.2010.12.001 |
0.662 |
|
| 2011 |
Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Bowtell DD, Harvey KF. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30: 2810-22. PMID 21317925 DOI: 10.1038/onc.2011.8 |
0.323 |
|
| 2011 |
Chan P, Möller A, Liu MC, Sceneay JE, Wong CS, Waddell N, Huang KT, Dobrovic A, Millar EK, O'Toole SA, McNeil CM, Sutherland RL, Bowtell DD, Fox SB. The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. Breast Cancer Research : Bcr. 13: R19. PMID 21306611 DOI: 10.1186/bcr2828 |
0.452 |
|
| 2011 |
Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL. The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Research : Bcr. 13: R16. PMID 21291529 DOI: 10.1186/bcr2825 |
0.826 |
|
| 2011 |
Xu H, Yan M, Patra J, Natrajan R, Yan Y, Swagemakers S, Tomaszewski JM, Verschoor S, Millar EK, van der Spek P, Reis-Filho JS, Ramsay RG, O'Toole SA, McNeil CM, Sutherland RL, ... ... Fox SB, et al. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Research : Bcr. 13: R9. PMID 21255398 DOI: 10.1186/bcr2814 |
0.338 |
|
| 2011 |
Davies JQ, Lin HH, Stacey M, Yona S, Chang GW, Gordon S, Hamann J, Campo L, Han C, Chan P, Fox SB. Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncology Reports. 25: 619-27. PMID 21174063 DOI: 10.3892/Or.2010.1117 |
0.405 |
|
| 2011 |
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 24: 157-67. PMID 21076464 DOI: 10.1038/modpathol.2010.200 |
0.35 |
|
| 2011 |
McKay M, Xu H, Yan M, Yan Y, Ramsay R, Sutherland R, Fox S. 755 poster ENHANCED RAD21 COHESIN EXPRESSION CONFERS POOR PROGNOSIS AND RESISTANCE TO CHEMOTHERAPY IN HIGH GRADE LUMINAL, BASAL AND HER2 BREAST CANCERS Radiotherapy and Oncology. 99: S299. DOI: 10.1016/S0167-8140(11)70877-5 |
0.362 |
|
| 2010 |
Margariti N, Fox SB, Bottini A, Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? Breast Cancer Research and Treatment. 128: 599-606. PMID 20945086 DOI: 10.1007/s10549-010-0986-9 |
0.508 |
|
| 2010 |
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schmitt FC, Tan PH, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research : Bcr. 12: 207. PMID 20804570 DOI: 10.1186/bcr2607 |
0.376 |
|
| 2010 |
Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Research and Treatment. 123: 795-804. PMID 20680681 DOI: 10.1007/s10549-010-1063-0 |
0.821 |
|
| 2010 |
Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, Morrison BJ, Vargas AC, Healey S, Beesley J, Pakkiri P, Parry S, Kurniawan N, Reid L, Keith P, ... ... Fox S, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Research : Bcr. 12: R46. PMID 20604919 DOI: 10.1186/Bcr2603 |
0.311 |
|
| 2010 |
Yan M, Rayoo M, Takano EA, Fox SB. Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Research and Treatment. 126: 395-405. PMID 20490651 DOI: 10.1007/s10549-010-0941-9 |
0.374 |
|
| 2010 |
Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Research. 70: 1573-84. PMID 20145130 DOI: 10.1158/0008-5472.CAN-09-3237 |
0.601 |
|
| 2010 |
Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment. 124: 79-88. PMID 20054642 DOI: 10.1007/s10549-009-0714-5 |
0.634 |
|
| 2010 |
Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment. 123: 661-77. PMID 19960244 DOI: 10.1007/S10549-009-0653-1 |
0.305 |
|
| 2010 |
Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, et al. Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. International Journal of Cancer. Journal International Du Cancer. 126: 1445-53. PMID 19676041 DOI: 10.1002/ijc.24826 |
0.444 |
|
| 2009 |
Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston G, Fox SB, et al. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. British Journal of Cancer. 101: 1749-57. PMID 19844231 DOI: 10.1038/sj.bjc.6605368 |
0.823 |
|
| 2009 |
Huang KT, Dobrovic A, Fox SB. No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. Bmc Research Notes. 2: 194. PMID 19778456 DOI: 10.1186/1756-0500-2-194 |
0.328 |
|
| 2009 |
Yan M, Rayoo M, Takano EA, Thorne H, Fox SB. BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. British Journal of Cancer. 101: 1168-74. PMID 19724277 DOI: 10.1038/sj.bjc.6605287 |
0.388 |
|
| 2009 |
Rayoo M, Yan M, Takano EA, Bates GJ, Brown PJ, Banham AH, Fox SB. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. Journal of Clinical Pathology. 62: 896-902. PMID 19622517 DOI: 10.1136/jcp.2009.065169 |
0.361 |
|
| 2009 |
Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banham AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1046-51. PMID 19188178 DOI: 10.1158/1078-0432.CCR-08-1507 |
0.798 |
|
| 2009 |
Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, O'Toole SA, McNeil CM, Crea P, Segara D, Sutherland RL, ... ... Fox SB, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. British Journal of Cancer. 100: 405-11. PMID 19165203 DOI: 10.1038/sj.bjc.6604844 |
0.784 |
|
| 2009 |
Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 227-34. PMID 19064988 DOI: 10.1200/JCO.2007.13.7083 |
0.797 |
|
| 2009 |
Rayoo M, Yan M, Takano EA, Fox SB. BRCA1 associated breast cancers are frequently positive for ER and its cytoplasmic expression confers a poor prognosis Pathology. 41: 51. DOI: 10.1097/01268031-200941001-00102 |
0.371 |
|
| 2008 |
Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2673-80. PMID 18451231 DOI: 10.1158/1078-0432.CCR-07-1046 |
0.794 |
|
| 2008 |
Qiu W, Hu M, Sridhar A, Opeskin K, Fox S, Shipitsin M, Trivett M, Thompson ER, Ramakrishna M, Gorringe KL, Polyak K, Haviv I, Campbell IG. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nature Genetics. 40: 650-5. PMID 18408720 DOI: 10.1038/ng.117 |
0.327 |
|
| 2008 |
Shaida N, Launchbury R, Boddy JL, Jones C, Campo L, Turley H, Kanga S, Banham AH, Malone PR, Harris AL, Fox SB. Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. The Prostate. 68: 336-43. PMID 18163427 DOI: 10.1002/pros.20707 |
0.815 |
|
| 2008 |
Bates GJ, Fox SB, Han C, Launchbury R, Leek RD, Harris AL, Banham AH. Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. Breast Cancer Research and Treatment. 111: 453-9. PMID 18026833 DOI: 10.1007/s10549-007-9812-4 |
0.746 |
|
| 2007 |
Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Research : Bcr. 9: 216. PMID 18190723 DOI: 10.1186/bcr1796 |
0.657 |
|
| 2007 |
Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. Breast Cancer Research : Bcr. 9: R89. PMID 18096060 DOI: 10.1186/bcr1838 |
0.788 |
|
| 2007 |
Gunningham SP, Currie MJ, Morrin HR, Tan EY, Turley H, Dachs GU, Watson AI, Frampton C, Robinson BA, Fox SB. The angiogenic factor thymidine phosphorylase up-regulates the cell adhesion molecule P-selectin in human vascular endothelial cells and is associated with P-selectin expression in breast cancers. The Journal of Pathology. 212: 335-44. PMID 17487938 DOI: 10.1002/path.2174 |
0.648 |
|
| 2007 |
Banham AH, Boddy J, Launchbury R, Han C, Turley H, Malone PR, Harris AL, Fox SB. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. The Prostate. 67: 1091-8. PMID 17477366 DOI: 10.1002/pros.20583 |
0.821 |
|
| 2007 |
Fox SB, Launchbury R, Bates GJ, Han C, Shaida N, Malone PR, Harris AL, Banham AH. The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. The Prostate. 67: 623-9. PMID 17328069 DOI: 10.1002/pros.20538 |
0.407 |
|
| 2007 |
Generali D, Fox SB, Berruti A, Moore JW, Brizzi MP, Patel N, Allevi G, Bonardi S, Aguggini S, Bersiga A, Campo L, Dogliotti L, Bottini A, Harris AL. Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 550-8. PMID 17255277 DOI: 10.1158/1078-0432.CCR-06-1266 |
0.79 |
|
| 2007 |
Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, Harris AL, Fox SB. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 467-74. PMID 17255267 DOI: 10.1158/1078-0432.CCR-06-1466 |
0.798 |
|
| 2007 |
Generali D, Leek R, Fox SB, Moore JW, Taylor C, Chambers P, Harris AL. EGFR mutations in exons 18-21 in sporadic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 203-5. PMID 17220285 DOI: 10.1093/annonc/mdl322 |
0.733 |
|
| 2007 |
Lau YS, Danks L, Sun SG, Fox S, Sabokbar A, Harris A, Athanasou NA. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. Breast Cancer Research and Treatment. 105: 7-16. PMID 17151927 DOI: 10.1007/s10549-006-9438-y |
0.353 |
|
| 2007 |
Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4562-8. PMID 16899602 DOI: 10.1158/1078-0432.CCR-05-2690 |
0.821 |
|
| 2007 |
Generali DG, Berruti A, Fox SB, Brizzi M, Bonardi S, Milani M, Bersiga A, Dionisio R, Dogliotti L, Bottini A, Harris AL. Down-regulation of HIF-1α expression by letrozole in ER+ve breast cancer patients Journal of Clinical Oncology. 25: 510-510. DOI: 10.1200/JCO.2007.25.18_SUPPL.510 |
0.775 |
|
| 2007 |
Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First International Consensus on the Methodology of Lymphangiogenesis Quantification in Solid Human Tumors Cheminform. 38. DOI: 10.1002/CHIN.200725276 |
0.317 |
|
| 2006 |
Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5373-80. PMID 17135638 DOI: 10.1200/JCO.2006.05.9584 |
0.734 |
|
| 2006 |
Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB. First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. British Journal of Cancer. 95: 1611-25. PMID 17117184 DOI: 10.1038/Sj.Bjc.6603445 |
0.42 |
|
| 2006 |
Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer. 13: 921-30. PMID 16954440 DOI: 10.1677/erc.1.01216 |
0.829 |
|
| 2006 |
Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3623-8. PMID 16877730 DOI: 10.1200/JCO.2005.04.5773 |
0.769 |
|
| 2006 |
Bacon AL, Fox S, Turley H, Harris AL. Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. Oncogene. 26: 132-41. PMID 16799636 DOI: 10.1038/sj.onc.1209761 |
0.794 |
|
| 2006 |
Fox SB. Quantitative angiogenesis in breast cancer. Methods in Molecular Medicine. 120: 161-87. PMID 16491601 DOI: 10.1385/1-59259-969-9:161 |
0.344 |
|
| 2006 |
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute. 98: 262-72. PMID 16478745 DOI: 10.1093/jnci/djj052 |
0.513 |
|
| 2006 |
Generali DG, Fox S, Buffa FM, Berruti A, Brizzi M, Allevi G, Bonardi S, Dogliotti L, Bottini A, Harris A. Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients Journal of Clinical Oncology. 24: 618-618. DOI: 10.1200/jco.2006.24.18_suppl.618 |
0.583 |
|
| 2006 |
Sooriakumaran P, Macanas-Pirard P, Fox S, Coley H, Bucca G, Lovell D, Henderson A, Smith C, Langley S, Laing R. A blinded, randomized controlled trial of neo-adjuvant celecoxib in patients with early prostate cancer Journal of Clinical Oncology. 24: 4563-4563. DOI: 10.1200/JCO.2006.24.18_SUPPL.4563 |
0.313 |
|
| 2005 |
Ah-See ML, Burcombe RJ, Daley FM, Richman PI, Padhani AR, Bentzen SM, Fox SB, Harris AL, Makris A. Evaluation of tumour microvessel density & pericyte coverage index following neoadjuvant chemotherapy in primary breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 655. PMID 27946122 DOI: 10.1200/Jco.2005.23.16_Suppl.655 |
0.528 |
|
| 2005 |
Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, Malone PR, Harris AL. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer Clinical Cancer Research. 11: 7658-7663. PMID 16278385 DOI: 10.1158/1078-0432.CCR-05-0460 |
0.811 |
|
| 2005 |
Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Research and Treatment. 93: 237-46. PMID 16172796 DOI: 10.1007/S10549-005-5157-Z |
0.493 |
|
| 2005 |
Campo L, Turley H, Han C, Pezzella F, Gatter KC, Harris AL, Fox SB. Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. The Journal of Pathology. 205: 585-91. PMID 15776477 DOI: 10.1002/path.1740 |
0.796 |
|
| 2005 |
Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 112: 413-30. PMID 15563306 DOI: 10.1111/j.1600-0463.2004.apm11207-0803.x |
0.426 |
|
| 2005 |
Boddy J, Fox S, Cheng H, Hurley H, Brown P, Malone P, Banham A, Harris A. 885Co-expression of the forkhead transcription factor, FOXPI with the androgen receptor in human prostate cancer, support its role as a potential co-regulator of this receptor European Urology Supplements. 4: 224. DOI: 10.1016/S1569-9056(05)80889-9 |
0.75 |
|
| 2005 |
Boddy JL, Fox SB, Cheng H, Hurley H, Brown P, Malone PR, Harris AL. 237: Expression of the Androgen Receptor in Prostate Cancer is related to Vascular Endothelial Growth Factor and Hypoxia Inducible Factors 1: and 2 Journal of Urology. 173: 65-65. DOI: 10.1016/s0022-5347(18)34502-6 |
0.774 |
|
| 2004 |
Sotiriou C, Paesmans M, Harris A, Colozza MA, Fox S, Taylor M, Sorre A, Martiat P, Cardoso F, Piccart M. Cyclin E1 (CCNE1) and E2 (CCNE2) as prognostic and predictive markers for endocrine therapy (ET) in early breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9504. PMID 28016802 DOI: 10.1200/jco.2004.22.14_suppl.9504 |
0.33 |
|
| 2004 |
Van der Auwera I, Van Laere SJ, Van den Eynden GG, Benoy I, van Dam P, Colpaert CG, Fox SB, Turley H, Harris AL, Van Marck EA, Vermeulen PB, Dirix LY. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 7965-71. PMID 15585631 DOI: 10.1158/1078-0432.Ccr-04-0063 |
0.697 |
|
| 2004 |
Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Research. 64: 6563-70. PMID 15374969 DOI: 10.1158/0008-5472.CAN-03-3176 |
0.773 |
|
| 2004 |
Fox SB, Bragança J, Turley H, Campo L, Han C, Gatter KC, Bhattacharya S, Harris AL. CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. Cancer Research. 64: 6075-81. PMID 15342390 DOI: 10.1158/0008-5472.Can-04-0708 |
0.721 |
|
| 2004 |
Chakrabarti J, Turley H, Campo L, Han C, Harris AL, Gatter KC, Fox SB. The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. British Journal of Cancer. 91: 954-8. PMID 15328513 DOI: 10.1038/sj.bjc.6602059 |
0.741 |
|
| 2004 |
Currie MJ, Hanrahan V, Gunningham SP, Morrin HR, Frampton C, Han C, Robinson BA, Fox SB. Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. Journal of Clinical Pathology. 57: 829-34. PMID 15280403 DOI: 10.1136/jcp.2003.015644 |
0.343 |
|
| 2004 |
Fox SB, Brown P, Han C, Ashe S, Leek RD, Harris AL, Banham AH. Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3521-7. PMID 15161711 DOI: 10.1158/1078-0432.CCR-03-0461 |
0.73 |
|
| 2004 |
Fox SB, Turley H, Cheale M, Blázquez C, Roberts H, James N, Cook N, Harris A, Gatter K. Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. The Journal of Pathology. 202: 313-20. PMID 14991896 DOI: 10.1002/path.1520 |
0.656 |
|
| 2004 |
Sowter HM, Ferguson M, Pym C, Watson P, Fox SB, Han C, Harris AL. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. The Journal of Pathology. 201: 573-80. PMID 14648660 DOI: 10.1002/path.1486 |
0.783 |
|
| 2004 |
Ord JJ, Cranston D, Harris AL, Campo L, Turley H, Allen P, Fox S, Davies DR. 773: C-KIT and CK7 Immunohistochemistry in the Differential Diagnosis of Renal Cell Carcinoma, A Study of 111 Cases Journal of Urology. 171: 205-205. DOI: 10.1016/s0022-5347(18)38022-4 |
0.582 |
|
| 2003 |
Colpaert CG, Vermeulen PB, Fox SB, Harris AL, Dirix LY, Van Marck EA. The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Research and Treatment. 81: 137-47. PMID 14572156 DOI: 10.1023/A:1025702330207 |
0.495 |
|
| 2003 |
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proceedings of the National Academy of Sciences of the United States of America. 100: 10393-8. PMID 12917485 DOI: 10.1073/Pnas.1732912100 |
0.459 |
|
| 2003 |
Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, Fox SB. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. The Journal of Pathology. 200: 183-94. PMID 12754739 DOI: 10.1002/path.1339 |
0.799 |
|
| 2003 |
Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Roy F, van Beest P, Goovaerts G, Dirix LY, van Dam P, Fox SB, Harris AL, van Marck EA. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. British Journal of Cancer. 88: 718-25. PMID 12618881 DOI: 10.1038/sj.bjc.6600807 |
0.549 |
|
| 2002 |
Currie MJ, Gunningham SP, Turner K, Han C, Scott PA, Robinson BA, Chong W, Harris AL, Fox SB. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. The Journal of Pathology. 198: 502-10. PMID 12434420 DOI: 10.1002/path.1228 |
0.791 |
|
| 2002 |
Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M, Beliën JA, de Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL, Dirix LY. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. European Journal of Cancer (Oxford, England : 1990). 38: 1564-79. PMID 12142044 |
0.337 |
|
| 2002 |
Fox SB, Gasparini G, Harris AL. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. The Lancet. Oncology. 2: 278-89. PMID 11905783 DOI: 10.1016/S1470-2045(00)00323-5 |
0.462 |
|
| 2001 |
Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. The Journal of Pathology. 195: 236-43. PMID 11592104 DOI: 10.1002/path.931 |
0.537 |
|
| 2001 |
Gunningham SP, Currie MJ, Han C, Robinson BA, Scott PA, Harris AL, Fox SB. VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. The Journal of Pathology. 193: 325-32. PMID 11241411 DOI: 10.1002/path.814 |
0.534 |
|
| 2000 |
Kakolyris S, Fox SB, Koukourakis M, Giatromanolaki A, Brown N, Leek RD, Taylor M, Leigh IM, Gatter KC, Harris AL. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. British Journal of Cancer. 82: 844-51. PMID 10732757 DOI: 10.1054/bjoc.1999.1010 |
0.545 |
|
| 2000 |
Fox SB, Gatter KC, Leek RD, Harris AL, Chew KL, Mayall BH, Moore DH. More about: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. Journal of the National Cancer Institute. 92: 161-2. PMID 10639519 DOI: 10.1093/jnci/92.2.161 |
0.703 |
|
| 1999 |
Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 10: 707-13. PMID 10442194 DOI: 10.1023/A:1008303614441 |
0.537 |
|
| 1998 |
Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. British Journal of Cancer. 77: 2246-51. PMID 9649140 DOI: 10.1038/bjc.1998.373 |
0.712 |
|
| 1998 |
Kakolyris S, Kaklamanis L, Engels K, Fox SB, Taylor M, Hickson ID, Gatter KC, Harris AL. Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis. British Journal of Cancer. 77: 1169-73. PMID 9569057 DOI: 10.1038/bjc.1998.194 |
0.53 |
|
| 1997 |
Fox SB, Harris AL. The epidermal growth factor receptor in breast cancer Journal of Mammary Gland Biology and Neoplasia. 2: 131-141. PMID 10882299 |
0.472 |
|
| 1997 |
Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. The Journal of Pathology. 182: 414-20. PMID 9306962 DOI: 10.1002/(SICI)1096-9896(199708)182:4<414::AID-PATH897>3.0.CO;2-Q |
0.584 |
|
| 1997 |
Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. Journal of the National Cancer Institute. 89: 1044-9. PMID 9230886 DOI: 10.1093/JNCI/89.14.1044 |
0.701 |
|
| 1997 |
Fox SB, Harris AL. Markers of tumor angiogenesis: Clinical applications in prognosis and anti-angiogenic therapy Investigational New Drugs. 15: 15-28. PMID 9195286 DOI: 10.1023/A:1005714527315 |
0.424 |
|
| 1997 |
Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC, Harris AL. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 8: 271-5. PMID 9137797 DOI: 10.1023/A:1008280110558 |
0.696 |
|
| 1997 |
Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. The Journal of Pathology. 181: 207-12. PMID 9120727 DOI: 10.1002/(SICI)1096-9896(199702)181:2<207::AID-PATH758>3.0.CO;2-4 |
0.482 |
|
| 1997 |
Engels K, Fox SB, Harris AL. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. Exs. 79: 113-56. PMID 9002231 DOI: 10.1007/978-3-0348-9006-9_6 |
0.497 |
|
| 1997 |
Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Human Pathology. 27: 1149-55. PMID 8912823 DOI: 10.1016/S0046-8177(96)90307-X |
0.765 |
|
| 1996 |
Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. European Journal of Cancer (Oxford, England : 1990). 32: 2474-84. PMID 9059336 DOI: 10.1016/S0959-8049(96)00379-6 |
0.534 |
|
| 1996 |
Harris AL, Zhang H, Moghaddam A, Fox S, Scott P, Pattison A, Gatter K, Stratford I, Bicknell R. Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. Breast Cancer Research and Treatment. 38: 97-108. PMID 8825127 DOI: 10.1007/BF01803788 |
0.532 |
|
| 1996 |
Fox SB, Gatter KC, Harris AL. Tumour angiogenesis. The Journal of Pathology. 179: 232-7. PMID 8774475 DOI: 10.1002/(sici)1096-9896(199607)179:3<232::aid-path505>3.0.co;2-a |
0.397 |
|
| 1996 |
Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC, Harris AL. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. British Journal of Cancer. 73: 275-80. PMID 8562330 DOI: 10.1038/bjc.1996.49 |
0.725 |
|
| 1996 |
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC, Harris AL. Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. The Journal of Pathology. 177: 275-83. PMID 8551390 DOI: 10.1002/PATH.1711770310 |
0.709 |
|
| 1996 |
Fox SB, Turner GD, Leek RD, Whitehouse RM, Gatter KC, Harris AL. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Research and Treatment. 36: 219-26. PMID 8534869 DOI: 10.1007/BF00666042 |
0.693 |
|
| 1995 |
Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas. The Journal of Urology. 154: 237-41. PMID 7776437 DOI: 10.1016/S0022-5347(01)67286-0 |
0.443 |
|
| 1995 |
Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, Harris AL. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. The Journal of Pathology. 176: 183-90. PMID 7636628 DOI: 10.1002/path.1711760212 |
0.624 |
|
| 1995 |
Harris AL, Fox S, Leek R, Zhang H, Scott P, Bicknell R, Gatter K. Breast cancer angiogenesis: therapy target and prognostic factor. European Journal of Cancer (Oxford, England : 1990). 831-2. PMID 7543767 DOI: 10.1016/0959-8049(95)00129-7 |
0.72 |
|
| 1995 |
Moghaddam A, Zhang HT, Fan TP, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 92: 998-1002. PMID 7532308 DOI: 10.1073/pnas.92.4.998 |
0.687 |
|
| 1995 |
Macaulay VM, Fox SB, Zhang H, Whitehouse RM, Leek RD, Gatter KC, Bicknell R, Harris AL. Breast cancer angiogenesis and tamoxifen resistance Endocrine Related Cancer. 2: 97-103. DOI: 10.1677/erc.0.0020097 |
0.705 |
|
| 1995 |
Caffo O, Barbareschi M, Veronese S, Pezzella F, Leek R, Fox S, Harris A, Dalla Palma P. 686 BCL2 expression in node-negative breast carcinoma: A study on a series of 190 cases with long-term follow-up European Journal of Cancer. 31: S143. DOI: 10.1016/0959-8049(95)95936-Z |
0.75 |
|
| 1994 |
Harris AL, Fox S, Bicknell R, Leek R, Relf M, LeJeune S, Kaklamanis L. Gene therapy through signal transduction pathways and angiogenic growth factors as therapeutic targets in breast cancer. Cancer. 74: 1021-5. PMID 8039135 DOI: 10.1002/1097-0142(19940801)74:3+<1021::AID-CNCR2820741508>3.0.CO;2-1 |
0.716 |
|
| 1994 |
Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Research and Treatment. 29: 41-49. PMID 8018963 DOI: 10.1007/Bf00666180 |
0.454 |
|
| 1994 |
Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. British Journal of Urology. 74: 762-6. PMID 7530131 DOI: 10.1111/j.1464-410X.1994.tb07122.x |
0.396 |
|
| 1994 |
Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL. Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment. 29: 109-116. PMID 7517221 DOI: 10.1007/Bf00666186 |
0.744 |
|
| 1993 |
Rogers S, Day CA, Fox SB. Expression of cathepsin D and estrogen receptor in male breast carcinoma. Human Pathology. 24: 148-51. PMID 8381763 DOI: 10.1016/0046-8177(93)90293-p |
0.329 |
|
| 1993 |
Fox S, Stuart N, Smith K, Brunner N, Harris A. High levels of uPA and PA1 are associated with highly angiogenic breast carcinomas The Breast. 2: 206. DOI: 10.1016/0960-9776(93)90148-9 |
0.45 |
|
| 1993 |
Fox S, Gatter K, Bicknell R, Going J, Cooke T, Harris A. Endothelial cell proliferation in human breast carcinoma The Breast. 2: 206. DOI: 10.1016/0960-9776(93)90147-8 |
0.482 |
|
| 1992 |
Fox SB, Rogers S, Day CA, Underwood JC. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. The Journal of Pathology. 166: 13-8. PMID 1538271 DOI: 10.1002/path.1711660104 |
0.339 |
|
| 1991 |
Fox SB, Day CA, Rogers S. Lack of c-erbB-2 oncoprotein expression in male breast carcinoma. Journal of Clinical Pathology. 44: 960-1. PMID 1684366 DOI: 10.1136/jcp.44.11.960 |
0.32 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2017 |
Raghu D, Jan Paul P, Gulati T, Deb S, Khoo C, Russo A, Gallo E, Blandino G, Chan AL, Takano E, Sandhu SK, Fox SB, Williams S, Haupt S, Gamell C, et al. E6AP promotes prostate cancer by reducing p27 expression. Oncotarget. PMID 28477016 DOI: 10.18632/oncotarget.17224 |
0.297 |
|
| 2021 |
Van Bockstal MR, François A, Altinay S, Arnould L, Balkenhol M, Broeckx G, Burguès O, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Hastir D, et al. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 34218258 DOI: 10.1038/s41379-021-00865-z |
0.296 |
|
| 2013 |
Deb S, Do H, Byrne D, Jene N, Dobrovic A, Fox SB. PIK3CA mutations are frequently observed in BRCAX but not BRCA2-associated male breast cancer. Breast Cancer Research : Bcr. 15: R69. PMID 23971979 DOI: 10.1186/bcr3463 |
0.295 |
|
| 2019 |
Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, et al. Molecular comparison of interval and screen-detected breast cancers. The Journal of Pathology. PMID 30746706 DOI: 10.1002/path.5251 |
0.294 |
|
| 2009 |
Yan M, Fox SB. Does cyclin D1 discriminate between BRCA2 and BRCAX breast cancers? Histopathology. 55: 625-6. PMID 19780858 DOI: 10.1111/j.1365-2559.2009.03396.x |
0.294 |
|
| 2021 |
Zelli V, Silvestri V, Valentini V, Bucalo A, Rizzolo P, Zanna I, Bianchi S, Coppa A, Giannini G, Cortesi L, Calistri D, Tibiletti MG, Fox SB, Fab K, Palli D, et al. Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. Cancers. 13. PMID 34572741 DOI: 10.3390/cancers13184515 |
0.294 |
|
| 2023 |
Thorne H, Devereux L, Li J, Alsop K, Christie L, van Geelen CT, Burdett N, Pishas KI, Woodford N, Leditschke J, Izzath MHMA, Strachan K, Young G, Jaravaza RD, Madadin MS, ... ... Fox S, et al. BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme. Histopathology. PMID 36999648 DOI: 10.1111/his.14906 |
0.293 |
|
| 2008 |
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5198-208. PMID 18698038 DOI: 10.1158/1078-0432.Ccr-08-0196 |
0.292 |
|
| 2023 |
Feng Y, McGuire N, Walton A, Fox S, Papa A, Lakhani SR, McCart Reed AE. Predicting breast cancer-specific survival in metaplastic breast cancer patients using machine learning algorithms. Journal of Pathology Informatics. 14: 100329. PMID 37664452 DOI: 10.1016/j.jpi.2023.100329 |
0.292 |
|
| 2017 |
Gamell C, Gulati T, Levav-Cohen Y, Young RJ, Do H, Pilling P, Takano E, Watkins N, Fox SB, Russell P, Ginsberg D, Monahan BJ, Wright G, Dobrovic A, Haupt S, et al. Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer. Science Signaling. 10. PMID 28074012 DOI: 10.1126/Scisignal.Aaf8223 |
0.29 |
|
| 2013 |
Pang JM, Dobrovic A, Fox SB. DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Research : Bcr. 15: 206. PMID 23826974 DOI: 10.1186/bcr3420 |
0.289 |
|
| 2014 |
De Campos Silva T, Deb S, Xu H, Yan Y, Fox SB, Mortensen N, McKay M. Effect of RAD21 overexpression on prognosis in KRAS-mutant colorectal carcinomas. Journal of Clinical Oncology. 32: 453-453. DOI: 10.1200/JCO.2014.32.3_SUPPL.453 |
0.288 |
|
| 2016 |
Pang JB, Gorringe KL, Fox SB. Response to "The Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast". Histopathology. PMID 26990228 DOI: 10.1111/his.12968 |
0.287 |
|
| 2020 |
Zhao Y, Pan Z, Namburi S, Pattison A, Posner A, Balachander S, Paisie CA, Reddi HV, Rueter J, Gill AJ, Fox S, Raghav KPS, Flynn WF, Tothill RW, Li S, et al. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. Ebiomedicine. 61: 103030. PMID 33039710 DOI: 10.1016/j.ebiom.2020.103030 |
0.287 |
|
| 2013 |
Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi PP, Castillo-Martin M, Bonal DM, Cordon-Cardo C, Lozano G, Haupt Y. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle (Georgetown, Tex.). 12: 1722-31. PMID 23656786 DOI: 10.4161/Cc.24805 |
0.286 |
|
| 2011 |
Salto-Tellez M, Yau EX, Yan B, Fox SB. Where and by whom should gastric cancer HER2/neu status be assessed?: lessons from breast cancer. Archives of Pathology & Laboratory Medicine. 135: 693-5. PMID 21631260 DOI: 10.1043/2011-0084-ED.1 |
0.285 |
|
| 2014 |
Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nature Reviews. Cancer. 14: 159-72. PMID 24561443 DOI: 10.1038/nrc3677 |
0.284 |
|
| 2016 |
Gorringe K, Hunter S, Byrne D, Devereux L, Rowley S, Elder K, Huynh R, Pridmore V, Hopper J, Kavanagh A, Mitchell G, Mann B, Fox S, Campbell I. Abstract P6-02-04: Screen detected and interval cancers; genomic analysis points to different molecular etiology? Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-02-04 |
0.284 |
|
| 2002 |
Vermeulen PB, Fox SB, Dirix LY, Colpaert C, Van Marck EA. Heterogeneity of vascularisation in invasive breast carcinoma. European Journal of Cancer (Oxford, England : 1990). 38: 1951-2. PMID 12204679 DOI: 10.1016/S0959-8049(02)00156-9 |
0.282 |
|
| 2017 |
Hendry S, Pang JB, Byrne D, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL, Fox SB. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinico-pathological and genetic features. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28611201 DOI: 10.1158/1078-0432.CCR-17-0743 |
0.282 |
|
| 2019 |
Savas P, Virassamy B, Ye C, Salim A, Mintoff C, Caramia F, Salgado R, Teo Z, Dushyanthen S, Byrne A, Luen S, Fox S, Speed T, Mackay L, Neeson P, et al. Abstract PD5-03: Characterization of high TIL breast cancers reveals a prognostic and functionally distinct tissue-resident memory subpopulation Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd5-03 |
0.282 |
|
| 2009 |
Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine. 15: 907-13. PMID 19648928 DOI: 10.1038/nm.2000 |
0.282 |
|
| 2021 |
Dinh P, Graham JD, Elder EN, Kabir M, Doan TB, French J, Meybodi F, Hui R, Wilcken NR, Harnett PR, Hsu J, Stuart KE, Wang T, Ahern V, Brennan M, ... Fox SB, et al. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing. Breast Cancer Research and Treatment. PMID 34853987 DOI: 10.1007/s10549-021-06456-5 |
0.281 |
|
| 2014 |
Lightfoot N, Tawfik B, Fox SB. Diagnostic issues with significant tumour displacement in breast biopsies. Journal of Clinical Pathology. 67: 1110-1. PMID 25214055 DOI: 10.1136/jclinpath-2014-202450 |
0.281 |
|
| 2020 |
Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, ... ... Fox SB, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer. 6: 17. PMID 32411819 DOI: 10.1038/s41523-020-0156-0 |
0.28 |
|
| 2019 |
Karnezis T, Farnsworth R, Harris NC, Williams SP, Caesar C, Byrne DJ, Herle P, Macheda ML, Shayan R, Zhang YF, Yazar S, Takouridis SJ, Gerard C, Fox S, Achen MG, et al. CCL27/CCL28-CCR10 CHEMOKINE SIGNALING MEDIATES MIGRATION OF LYMPHATIC ENDOTHELIAL CELLS. Cancer Research. PMID 30709930 DOI: 10.1158/0008-5472.Can-18-1858 |
0.28 |
|
| 2024 |
Meyer B, Stirzaker C, Ramkomuth S, Harvey K, Chan B, Lee CS, Karim R, Deng N, Avery-Kiejda KA, Scott RJ, Lakhani S, Fox S, Robbins E, Shin JS, Beith J, et al. Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma. The Journal of Pathology. PMID 38300122 DOI: 10.1002/path.6250 |
0.279 |
|
| 2017 |
Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB, Perou CM, Visvader JE, Gray DHD, Loi S, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Science Translational Medicine. 9. PMID 28592566 DOI: 10.1126/Scitranslmed.Aal4922 |
0.279 |
|
| 2011 |
Smith LD, Tesoriero AA, Wong EM, Ramus SJ, O'Malley FP, Mulligan AM, Terry MB, Senie RT, Santella RM, John EM, Andrulis IL, Ozcelik H, Daly MB, Godwin AK, Buys SS, ... Fox S, et al. Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Research : Bcr. 13: R14. PMID 21281505 DOI: 10.1186/Bcr2822 |
0.275 |
|
| 2022 |
Tan BY, Fox SB, Lakhani SR, Tan PH. Survey of recurrent diagnostic challenges in breast phyllodes tumours. Histopathology. 82: 95-105. PMID 36468287 DOI: 10.1111/his.14730 |
0.274 |
|
| 2015 |
Pang JM, Byrne DJ, Takano EA, Jene N, Petelin L, McKinley J, Poliness C, Saunders C, Taylor D, Mitchell G, Fox SB. Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer. Plos One. 10: e0128861. PMID 26110820 DOI: 10.1371/journal.pone.0128861 |
0.273 |
|
| 2019 |
Farshid G, Bilous M, Morey A, Fox S, Lakhani S, Loi S, Bell R, Spillane A. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. Pathology. PMID 31076089 DOI: 10.1016/j.pathol.2019.02.004 |
0.273 |
|
| 2010 |
Huang KT, Mikeska T, Dobrovic A, Fox SB. DNA methylation analysis of the HIF-1α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. Histopathology. 57: 451-60. PMID 20727020 DOI: 10.1111/j.1365-2559.2010.03633.x |
0.273 |
|
| 2012 |
Karnezis T, Shayan R, Caesar C, Roufail S, Harris NC, Ardipradja K, Zhang YF, Williams SP, Farnsworth RH, Chai MG, Rupasinghe TW, Tull DL, Baldwin ME, Sloan EK, Fox SB, et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell. 21: 181-95. PMID 22340592 DOI: 10.1016/j.ccr.2011.12.026 |
0.273 |
|
| 2017 |
Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O'Toole SA, Lakhani SR, Cummings MC, ... ... Fox SB, et al. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 28338653 DOI: 10.1038/modpathol.2017.21 |
0.272 |
|
| 2011 |
Wong EM, Southey MC, Fox SB, Brown MA, Dowty JG, Jenkins MA, Giles GG, Hopper JL, Dobrovic A. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prevention Research (Philadelphia, Pa.). 4: 23-33. PMID 20978112 DOI: 10.1158/1940-6207.CAPR-10-0212 |
0.272 |
|
| 2004 |
Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. The Journal of Pathology. 203: 721-8. PMID 15141388 DOI: 10.1002/path.1565 |
0.272 |
|
| 2009 |
Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, ... ... Fox S, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1417-27. PMID 19193619 DOI: 10.1158/1078-0432.Ccr-08-1564 |
0.271 |
|
| 2016 |
Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 68: 5-21. PMID 26768026 DOI: 10.1111/his.12876 |
0.27 |
|
| 2016 |
Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, et al. Phyllodes tumours of the breast: A consensus review Histopathology. 68: 5-21. DOI: 10.1111/his.12876 |
0.27 |
|
| 2010 |
Huang KT, Dobrovic A, Fox SB. No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer. Breast Cancer Research and Treatment. 124: 853-6. PMID 20680678 DOI: 10.1007/s10549-010-1087-5 |
0.269 |
|
| 2012 |
Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, Fox SB, Francis GD, Waite B, McCue G, Raymond WA, Robbins PD, Farshid G. Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Research and Treatment. 134: 617-24. PMID 22678156 DOI: 10.1007/s10549-012-2093-6 |
0.268 |
|
| 2022 |
Udayasiri RI, Luo T, Gorringe KL, Fox SB. Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast. Histopathology. 82: 106-118. PMID 36482277 DOI: 10.1111/his.14804 |
0.268 |
|
| 2014 |
Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam K, Veillard AS, Stricker P, Haupt S, Haupt Y, Horvath L, Fox SB. Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 2392-7. PMID 25231954 DOI: 10.1093/annonc/mdu454 |
0.268 |
|
| 2016 |
Millen R, Malaterre J, Cross RS, Carpinteri S, Desai J, Tran B, Darcy P, Gibbs P, Sieber O, Zeps N, Waring P, Fox S, Pereira L, Ramsay RG. Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. Oncoimmunology. 5: e1149667. PMID 27622014 DOI: 10.1080/2162402X.2016.1149667 |
0.268 |
|
| 2019 |
Dano H, Altinay S, Arnould L, Bletard N, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Jaffer S, Kurpershoek E, Lacroix-Triki M, Laka A, et al. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 31534203 DOI: 10.1038/s41379-019-0367-9 |
0.268 |
|
| 2010 |
Farshid G, Armes JE, Bell R, Cummings M, Fox S, Francis G, Haswell M, Morey A, McCue G, Raymond W, Robbins P, Bilous M. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B. 19: 187-93. PMID 21052003 DOI: 10.1097/PDM.0b013e3181e1cc9d |
0.267 |
|
| 2019 |
McEvoy CR, Xu H, Smith K, Etemadmoghadam D, Leong HS, Choong DY, Byrne DJ, Iravani A, Beck S, Mileshkin L, Tothill RW, Bowtell DD, Bates BM, Nastevski V, Browning J, ... ... Fox SB, et al. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. The Journal of Clinical Investigation. 130. PMID 30835257 DOI: 10.1172/JCI123089 |
0.267 |
|
| 2015 |
James PA, Sawyer S, Boyle S, Young MA, Kovalenko S, Doherty R, McKinley J, Alsop K, Beshay V, Harris M, Fox S, Lindeman GJ, Mitchell G. Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. Familial Cancer. 14: 287-95. PMID 25678442 DOI: 10.1007/s10689-015-9785-0 |
0.267 |
|
| 2016 |
Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research : Bcr. 18: 15. PMID 26857456 DOI: 10.1186/S13058-016-0671-Y |
0.265 |
|
| 2022 |
Mejía-Hernández JO, Raghu D, Caramia F, Clemons N, Fujihara K, Riseborough T, Teunisse A, Jochemsen AG, Abrahmsén L, Blandino G, Russo A, Gamell C, Fox SB, Mitchell C, Takano EA, et al. Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. Cancers. 14. PMID 36010941 DOI: 10.3390/cancers14163947 |
0.265 |
|
| 2015 |
Yan M, Shield-Artin K, Byrne D, Deb S, Waddell N, Haviv I, Fox SB. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. Bmc Cancer. 15: 506. PMID 26152113 DOI: 10.1186/s12885-015-1522-4 |
0.263 |
|
| 2011 |
Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Molecular and Cellular Biology. 31: 4609-22. PMID 21930782 DOI: 10.1128/MCB.05766-11 |
0.26 |
|
| 2024 |
Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, Vieth M, Hida AI, Kahila M, Kos Z, van Diest PJ, ... ... Fox SB, et al. Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology. PMID 38230434 DOI: 10.1002/path.6238 |
0.257 |
|
| 2015 |
Bolton D, Cheng Y, Willems-Jones AJ, Li J, Niedermeyr E, Mitchell G, Clouston D, Lawrentschuk N, Sliwinski A, Fox S, Thorne H. Altered significance of D'Amico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort. Bju International. 116: 207-12. PMID 24784491 DOI: 10.1111/bju.12792 |
0.257 |
|
| 2019 |
Luen SJ, Griguolo G, Nuciforo P, Campbell C, Fasani R, Cortes J, Untch M, Lin SJ, Savas P, Fox SB, Di Cosimo S, Llombart Cussac A, de Azambuja E, Piccart-Gebhart MJ, Pusztai L, et al. On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. Journal of Clinical Oncology. 37: 574-574. DOI: 10.1200/JCO.2019.37.15_SUPPL.574 |
0.253 |
|
| 2018 |
Elder K, Kader T, Hill P, Opeskin K, Goode D, Pang J, Fox S, Mann G, Campbell I, Gorringe K. Abstract P3-04-08: Genomic analysis of breast papillomas Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-04-08 |
0.253 |
|
| 2010 |
Ho I, Thorne H, Willems A, Clouston D, Fox S, Li J, Bolton D. 2154 BRCA2 MUTATION WITH A DIAGNOSIS OF PROSTATE CANCER FROM HIGH RISK BREAST CANCER FAMILIES CONFERS A SUBSTANTIALLY INCREASED RISK OF CANCER RELATED MORTALITY Journal of Urology. 183. DOI: 10.1016/J.JURO.2010.02.2256 |
0.253 |
|
| 2016 |
Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, et al. Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene. PMID 27641331 DOI: 10.1038/Onc.2016.159 |
0.252 |
|
| 1994 |
Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma British Journal of Urology. 74: 214-220. PMID 7921940 |
0.252 |
|
| 2023 |
Doig KD, Fellowes AP, Fox SB. Homologous Recombination Repair Deficiency: An Overview for Pathologists. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 36: 100049. PMID 36788098 DOI: 10.1016/j.modpat.2022.100049 |
0.251 |
|
| 2019 |
Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, ... ... Fox SB, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications. 10: 3935. PMID 31477716 DOI: 10.1038/S41467-019-11862-X |
0.251 |
|
| 2017 |
Rakha EA, Miligy I, Gorringe KL, Toss MS, Green AR, Fox SB, Schmitt FC, Tan PH, Tse GM, Badve S, Decker T, Vincent-Salomon A, Dabbs DJ, Foschini MP, Moreno F, et al. Invasion in breast lesions: the role of the epithelial-stroma barrier. Histopathology. PMID 29197112 DOI: 10.1111/his.13446 |
0.249 |
|
| 2013 |
Dabbs DJ, Schnitt SJ, Geyer FC, Weigelt B, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Lakhani SR, Palacios J, Rakha E, Richardson AL, Schmitt FC, Tan PH, et al. Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. The American Journal of Surgical Pathology. 37: e1-11. PMID 23759937 DOI: 10.1097/PAS.0b013e3182918a2b |
0.248 |
|
| 1993 |
Fox SB, Persad RA, Royds J, Kore RN, Silcocks PB, Collins CC. p53 and c-myc expression in stage A1 prostatic adenocarcinoma: Useful prognostic determinants? Journal of Urology. 150: 490-494. PMID 8326591 |
0.247 |
|
| 2017 |
Weeden CE, Holik AZ, Young RJ, Ma SB, Garnier JM, Fox SB, Antippa P, Irving LB, Steinfort DP, Wright GM, Russell PA, Ritchie ME, Burns CJ, Solomon B, Asselin-Labat ML. Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. Molecular Cancer Therapeutics. PMID 28611104 DOI: 10.1158/1535-7163.MCT-17-0174 |
0.246 |
|
| 2011 |
Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4803-10. PMID 22042947 DOI: 10.1200/Jco.2011.35.4928 |
0.245 |
|
| 2011 |
Cheng Y, Thorne H, Bolton D, Clouston D, Willems A, Li J, Niedermeyer E, Fox S, Mitchell G. 147 ALTERED SIGNIFICANCE OF D'AMICO RISK ASSESSMENT IN BRCA2 POSITIVE VS NEGATIVE PATIENTS FROM HIGH RISK BREAST CANCER FAMILIES Journal of Urology. 185. DOI: 10.1016/j.juro.2011.02.215 |
0.245 |
|
| 2017 |
Williams SP, Odell AF, Karnezis T, Farnsworth RH, Gould CM, Li J, Paquet-Fifield S, Harris NC, Walter A, Gregory JL, Lamont SF, Liu R, Takano EA, Nowell CJ, Bower NI, ... ... Fox SB, et al. Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. Science Signaling. 10. PMID 28974649 DOI: 10.1126/Scisignal.Aal2987 |
0.245 |
|
| 1997 |
Fox SB. Tumour angiogenesis and prognosis. Histopathology. 30: 294-301. PMID 9088964 DOI: 10.1046/j.1365-2559.1997.d01-606.x |
0.244 |
|
| 2006 |
Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R. Adrenomedullin and tumour angiogenesis. British Journal of Cancer. 94: 1-7. PMID 16251875 DOI: 10.1038/sj.bjc.6602832 |
0.242 |
|
| 2011 |
Lennerz JK, Kwak EL, Michael M, Fox SB, Ackerman A, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang Y, Clark JW, Solomon BJ, Iafrate AJ. Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4130. PMID 28021188 DOI: 10.1200/Jco.2011.29.15_Suppl.4130 |
0.242 |
|
| 2018 |
Zhang AY, Chiam K, Haupt Y, Fox SB, Birch S, Tilley W, Butler L, Knudsen KE, Cornstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Bohm M, Henshall SM, et al. An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy. Journal of Clinical Oncology. 36: 54-54. DOI: 10.1200/Jco.2018.36.6_Suppl.54 |
0.242 |
|
| 2015 |
Gorringe KL, Hunter SM, Pang JM, Opeskin K, Hill P, Rowley SM, Choong DY, Thompson ER, Dobrovic A, Fox SB, Mann GB, Campbell IG. Copy number analysis of ductal carcinoma in situ with and without recurrence. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 28: 1174-84. PMID 26321097 DOI: 10.1038/modpathol.2015.75 |
0.242 |
|
| 2016 |
Pang JM, Jene N, Fox SB. Assessing Tumor Angiogenesis in Histological Samples. Methods in Molecular Biology (Clifton, N.J.). 1430: 3-33. PMID 27172943 DOI: 10.1007/978-1-4939-3628-1_1 |
0.241 |
|
| 2009 |
Fox SB. Assessing tumor angiogenesis in histological samples. Methods in Molecular Biology (Clifton, N.J.). 467: 55-78. PMID 19301664 DOI: 10.1007/978-1-59745-241-0_3 |
0.241 |
|
| 2022 |
Md Nasir ND, Koh VCY, Cree IA, Indave Ruiz BI, Del Águila J, Armon S, Fox SB, Lakhani SR, Tan PH. Phyllodes tumour evidence gaps mapped from the 5th edition of the WHO classification of tumours of the breast. Histopathology. PMID 36579383 DOI: 10.1111/his.14856 |
0.241 |
|
| 2014 |
Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harell MI, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, et al. Abstract 38: Using molecularly characterized patient-derived models to delineate underlying drivers and vulnerabilities of epithelial ovarian cancer Cancer Research. 74: 38-38. DOI: 10.1158/1538-7445.Cansusc14-38 |
0.239 |
|
| 2017 |
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, ... ... Fox SB, et al. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology. PMID 28777142 DOI: 10.1097/Pap.0000000000000162 |
0.239 |
|
| 2020 |
Pang J, Castles B, Byrne D, Button P, Lakhani S, Sivasubramaniam V, Cooper W, Armes J, Millar E, Raymond W, Roberts-Thomson S, Kumar B, Burr M, Selinger C, Harvey K, ... ... Fox S, et al. 297P SP142 immunohistochemistry (IHC) PD-L1 inter- and intra-pathologist agreement in triple negative breast carcinoma (TNBC) Annals of Oncology. 31: S361. DOI: 10.1016/j.annonc.2020.08.399 |
0.239 |
|
| 2023 |
Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, ... ... Fox SB, et al. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology. PMID 37608771 DOI: 10.1002/path.6165 |
0.239 |
|
| 2017 |
Kumarasinghe MP, Morey A, Bilous M, Farshid G, Francis G, Lampe G, McCue G, Von Neumann-Cosel V, Fox SB. HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. Pathology. PMID 28823752 DOI: 10.1016/j.pathol.2017.05.009 |
0.238 |
|
| 2014 |
Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Molecular Oncology. 8: 656-68. PMID 24560445 DOI: 10.1016/J.Molonc.2014.01.008 |
0.238 |
|
| 2020 |
Kader T, Elder K, Zethoven M, Semple T, Hill P, Goode DL, Thio N, Cheasley D, Rowley SM, Byrne DJ, Pang JM, Miligy IM, Green AR, Rakha EA, Fox SB, et al. The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. Npj Breast Cancer. 6: 9. PMID 32195332 DOI: 10.1038/s41523-020-0150-6 |
0.237 |
|
| 2014 |
Pang JM, Deb S, Takano EA, Byrne DJ, Jene N, Boulghourjian A, Holliday A, Millar E, Lee CS, O'Toole SA, Dobrovic A, Fox SB. Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Research : Bcr. 16: 423. PMID 25331261 DOI: 10.1186/s13058-014-0423-9 |
0.236 |
|
| 2011 |
Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J, Clouston D, Mitchell G, Fox S, Hopper JL, Bolton D. Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prevention Research (Philadelphia, Pa.). 4: 1002-10. PMID 21733824 DOI: 10.1158/1940-6207.CAPR-10-0397 |
0.236 |
|
| 2011 |
Thorne H, Mitchell G, Fox S. kConFab: a familial breast cancer consortium facilitating research and translational oncology. Journal of the National Cancer Institute. Monographs. 2011: 79-81. PMID 22043047 DOI: 10.1093/jncimonographs/lgr042 |
0.235 |
|
| 2018 |
Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, ... ... Fox SB, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine. PMID 29942092 DOI: 10.1038/s41591-018-0078-7 |
0.235 |
|
| 2008 |
Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. Bmc Research Notes. 1: 14. PMID 18611285 DOI: 10.1186/1756-0500-1-14 |
0.235 |
|
| 2017 |
Hess D, Sebastian LT, Sjoquist KM, Lee CK, Hague W, Miller D, Cowley M, Qiu MR, Fox SB, Joshua AM, Simes J, Thomas DM. The Molecular Screening and Therapeutics (MoST) Program: A precision medicine framework for biomarker-driven signal-seeking clinical studies for rare cancers. Journal of Clinical Oncology. 35: TPS2621-TPS2621. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS2621 |
0.235 |
|
| 2014 |
Lim AM, Do H, Young RJ, Wong SQ, Angel C, Collins M, Takano EA, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Fox SB, Rischin D, Dobrovic A, et al. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. International Journal of Cancer. Journal International Du Cancer. 135: 887-95. PMID 24436120 DOI: 10.1002/ijc.28727 |
0.235 |
|
| 2017 |
Savas P, Teo ZL, Lefevre C, Flensburg C, Caramia F, Alsop K, Mansour M, Francis PA, Thorne HA, Silva MJ, Kanu N, Dietzen M, Rowan A, Kschischo M, Fox S, et al. Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". Plos Medicine. 14: e1002302. PMID 28430777 DOI: 10.1371/Journal.Pmed.1002302 |
0.235 |
|
| 2011 |
Alsop K, Fereday S, Meldrum C, deFazio A, Webb P, Birrer MJ, Friedlander M, Fox SB, Bowtell D, Mitchell G. Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5026. PMID 28023739 DOI: 10.1200/jco.2011.29.15_suppl.5026 |
0.234 |
|
| 2012 |
Takano EA, Rogers TM, Young RJ, Rayoo M, Kostos P, Ferguson R, Campbell IG, Debiec-Rychter M, Fox SB. The molecular characterisation of unusual subcutaneous spindle cell lesion of breast. Journal of Clinical Pathology. 65: 746-50. PMID 22523339 DOI: 10.1136/jclinpath-2011-200629 |
0.233 |
|
| 2013 |
Campbell I, Hunter S, Mathew W, Antill Y, Bae S, Ananda S, Topp M, Lipton L, Liauw W, Jobling T, Boussioutas A, Christie M, Allan P, Friedlander M, Fox S, et al. Abstract A3: Mucinous ovarian tumors: Are they all the same? Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A3 |
0.232 |
|
| 2022 |
Mejía-Hernández JO, Keam SP, Saleh R, Muntz F, Fox SB, Byrne D, Kogan A, Pang L, Huynh J, Litchfield C, Caramia F, Lozano G, He H, You JM, Sandhu S, et al. Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss. Cell Death & Disease. 13: 777. PMID 36075907 DOI: 10.1038/s41419-022-05211-y |
0.232 |
|
| 2022 |
Ligon JA, Sundby RT, Wedekind Malone MF, Arnaldez FI, Del Rivero J, Wiener L, Srinivasan R, Spencer M, Carbonell A, Lei H, Shern J, Steinberg SM, Figg WD, Peer CJ, Zimmerman S, ... ... Fox S, et al. A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-associated Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36302175 DOI: 10.1158/1078-0432.CCR-22-2168 |
0.232 |
|
| 2014 |
Tilch E, Seidens T, Cocciardi S, Reid LE, Byrne D, Simpson PT, Vargas AC, Cummings MC, Fox SB, Lakhani SR, Chenevix Trench G. Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Research and Treatment. 143: 385-92. PMID 24318467 DOI: 10.1007/S10549-013-2798-1 |
0.23 |
|
| 2014 |
Fer ND, Harris E, Fox S, Zhou M, Simpson C, Liu J, Korboukh I, Hull-Ryde EA, Janzen WP, Frye SV, Monks A, Teicher B, Rapisarda A. Abstract 3741: Development and characterization of a cell based assay for the validation of mutant IDH1 inhibitors Cancer Research. 74: 3741-3741. DOI: 10.1158/1538-7445.Am2014-3741 |
0.23 |
|
| 2012 |
Fox SB. Microscopic assessment of angiogenesis in tumors. Methods in Molecular Medicine. 46: 29-46. PMID 21340909 DOI: 10.1385/1-59259-143-4:029 |
0.23 |
|
| 2012 |
Sawyer S, Boyle S, Young M, Kovalenko S, Doherty R, McKinley J, Alsop K, Rehfisch M, Macaskill S, Ha A, Beshay V, Lindeman G, Harris M, Fox S, Mitchell G, et al. The contribution of LARGE genomic rearrangements of BRCA1 and BRCA2 gene mutations in breast and ovarian cancer families in a clinical cohort Hereditary Cancer in Clinical Practice. 10: 1-2. DOI: 10.1186/1897-4287-10-S2-A89 |
0.229 |
|
| 2020 |
Rakha E, Quinn CM, Pia Foschini M, Muñoz Martin M, Dabbs DJ, Lakhani S, Varga Z, Pinder SE, Schmitt FC, Reis-Filho JS, Fox SB, Ellis IO, Tan PH, Mihai R. Metaplastic carcinomas of the breast without evidence of epithelial differentiation: A diagnostic approach for management. Histopathology. PMID 33113154 DOI: 10.1111/his.14290 |
0.229 |
|
| 2020 |
Khuong-Quang DA, Brown LM, Wong M, Mayoh C, Sexton-Oates A, Kumar A, Pinese M, Nagabushan S, Lau L, Ludlow LE, Gifford AJ, Rodriguez M, Desai J, Fox SB, Haber M, et al. Recurrent SPECC1L-NTRK fusions in paediatric sarcoma and brain tumours. Cold Spring Harbor Molecular Case Studies. PMID 33144287 DOI: 10.1101/mcs.a005710 |
0.229 |
|
| 2020 |
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Laenkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice. The Journal of Pathology. PMID 32129476 DOI: 10.1002/Path.5406 |
0.228 |
|
| 2020 |
Kee D, Kondrashova O, Ananda S, Brown MP, Cohen PA, Dean A, Desai J, Fellowes A, Fox SB, Hadley A, Lindsay D, Mileshkin LR, O'Byrne KJ, Prall OW, Scott H, et al. NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment. Journal of Clinical Oncology. 38: 103-103. DOI: 10.1200/jco.2020.38.15_suppl.103 |
0.227 |
|
| 2011 |
Kumarasinghe MP, Morey A, Bilous M, Fox SB. Gastric HER2 testing study (GaTHER): Evaluation of gastric cancer testing accuracy in Australia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 15. PMID 27985794 DOI: 10.1200/jco.2011.29.4_suppl.15 |
0.227 |
|
| 2013 |
Young RJ, Lim AM, Angel C, Collins M, Deb S, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Russell PA, Wright G, McArthur GA, Fox SB, Rischin D, et al. Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. Oral Oncology. 49: 576-81. PMID 23434054 DOI: 10.1016/j.oraloncology.2013.01.006 |
0.226 |
|
| 2023 |
Posner A, Sivakumaran T, Pattison A, Etemadmoghadam D, Thio N, Wood C, Fisher K, Webb S, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, Collins IM, Richardson G, ... ... Fox SB, et al. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. Journal For Immunotherapy of Cancer. 11. PMID 36720497 DOI: 10.1136/jitc-2022-005809 |
0.226 |
|
| 2012 |
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2654-63. PMID 22711857 DOI: 10.1200/JCO.2011.39.8545 |
0.225 |
|
| 2019 |
Mileshkin LR, Sivakumaran T, Etemadmoghadam D, Tothill R, Fellowes A, Fox SB, Guccione L, Freimund AE, deFazio A, Wilcken N, Gao B, Singh MS, Collins IM, Richardson GE, Steer CB, et al. Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years. Journal of Clinical Oncology. 37: 3072-3072. DOI: 10.1200/JCO.2019.37.15_SUPPL.3072 |
0.223 |
|
| 2011 |
Kiely BE, Phillips K, Francis PA, Boyle FM, Forbes JF, Fox SB, Murphy L, Gebski V, Lindsay DF, Sutherland RL, Badger H. ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen-A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS126. PMID 28022934 DOI: 10.1200/jco.2011.29.15_suppl.tps126 |
0.222 |
|
| 2019 |
Gamell C, Bandilovska I, Gulati T, Kogan A, Lim SC, Kovacevic Z, Takano EA, Timpone C, Agupitan AD, Litchfield C, Blandino G, Horvath LG, Fox SB, Williams SG, Russo A, et al. E6AP Promotes a Metastatic Phenotype in Prostate Cancer. Iscience. 22: 1-15. PMID 31739170 DOI: 10.1016/j.isci.2019.10.065 |
0.222 |
|
| 2016 |
Pang JM, Gorringe KL, Fox SB. Ductal carcinoma in situ - update on risk assessment and management. Histopathology. 68: 96-109. PMID 26768032 DOI: 10.1111/his.12796 |
0.222 |
|
| 2001 |
Mori S, Fujieda S, Sunaga H, Fox SB, Saito H. Expression of platelet-derived endothelial cell growth factor and vascularity in the nasal mucosa from allergic rhinitis. Clinical and Experimental Allergy : Journal of the British Society For Allergy and Clinical Immunology. 30: 1637-44. PMID 11069574 DOI: 10.1046/j.1365-2222.2000.00903.x |
0.221 |
|
| 2015 |
Pang JM, Gorringe KL, Wong SQ, Dobrovic A, Campbell IG, Fox SB. Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. Breast Cancer Research : Bcr. 17: 80. PMID 26078038 DOI: 10.1186/s13058-015-0586-z |
0.22 |
|
| 2017 |
Flynn A, Dwight T, Benn D, Deb S, Colebatch AJ, Fox S, Harris J, Duncan EL, Robinson B, Hogg A, Ellul J, To H, Duong C, Miller JA, Yates C, et al. Cousins not twins: intra and inter-tumoral heterogeneity in syndromic neuroendocrine tumours. The Journal of Pathology. PMID 28369925 DOI: 10.1002/path.4900 |
0.22 |
|
| 2022 |
Posner A, Prall OWJ, Sivakumaran T, Etemadamoghadam D, Thio N, Pattison A, Balachander S, Fisher K, Webb S, Wood C, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, ... ... Fox SB, et al. A comparison of DNA sequencing and gene-expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. The Journal of Pathology. PMID 36287571 DOI: 10.1002/path.6022 |
0.219 |
|
| 2016 |
Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, ... ... Fox SB, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27363491 DOI: 10.1038/modpathol.2016.109 |
0.218 |
|
| 2018 |
Zhang AY, Chiam K, Haupt Y, Fox S, Birch S, Tilley W, Butler LM, Knudsen K, Comstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Ricciardelli C, Bohm M, et al. An Analysis of a Multiple Biomarker Panel to Better Predict Prostate Cancer Metastasis After Radical Prostatectomy. International Journal of Cancer. PMID 30288742 DOI: 10.1002/Ijc.31906 |
0.218 |
|
| 2013 |
Mitchell G, Campbell I, Dawkins H, Fox S, Hiller J, James P, Kirk J, Lindeman G, Macrae F, McGaughran J, Meiser B, Pachter N, Saunders C, Scott C, Suthers G, et al. An Introduction to ICCon - Inherited Cancer Connect Partnership Asia-Pacific Journal of Clinical Oncology. 9: 113-113. DOI: 10.1111/Ajco.12145 |
0.215 |
|
| 2005 |
Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, Munroe DJ, Farrar WL. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Research. 65: 4673-82. PMID 15930285 DOI: 10.1158/0008-5472.Can-04-3589 |
0.213 |
|
| 2023 |
O'Haire S, Franchini F, Kang YJ, Steinberg J, Canfell K, Desai J, Fox S, IJzerman M. Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours. Scientific Reports. 13: 4116. PMID 36914665 DOI: 10.1038/s41598-023-31055-3 |
0.212 |
|
| 2020 |
Millen R, Hendry S, Narasimhan V, Abbott R, Croxford M, Gibbs P, Tie J, Wong HL, Jones I, Kosmider S, Byrne D, Zalcberg J, Fox S, Desai J, Visvanathan K, et al. CD8 tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous metastatic colorectal carcinoma do not track with survival. Clinical & Translational Immunology. 9: e1155. PMID 32953115 DOI: 10.1002/Cti2.1155 |
0.212 |
|
| 2010 |
Handolias DD, Chan P, Phillips W, Fox SB, Pearson R, Sawyer S, Campbell I, Salemi R, McArthur GA. Activation of the PI3K pathway and prognostic information in epithelial ovarian cancer. Journal of Clinical Oncology. 28: 10610-10610. DOI: 10.1200/Jco.2010.28.15_Suppl.10610 |
0.211 |
|
| 2014 |
Busuttil RA, Zapparoli GV, Haupt S, Fennell C, Wong SQ, Pang JM, Takeno EA, Mitchell C, Di Costanzo N, Fox S, Haupt Y, Dobrovic A, Boussioutas A. Role of p53 in the progression of gastric cancer. Oncotarget. 5: 12016-26. PMID 25427447 DOI: 10.18632/ONCOTARGET.2434 |
0.21 |
|
| 2015 |
Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, Colebatch AJ, De Paoli-Iseppi R, Li J, Lupat R, Semple T, Arnau GM, Fellowes A, Leonard JH, Hruby G, ... ... Fox SB, et al. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research. PMID 26627015 DOI: 10.1158/0008-5472.Can-15-1877 |
0.21 |
|
| 2020 |
Prall OWJ, Nastevski V, Xu H, McEvoy CRE, Vissers JHA, Byrne DJ, Takano E, Yerneni S, Ellis S, Green T, Mitchell CA, Murray WK, Scott CL, Grimmond SM, Hofmann O, ... ... Fox SB, et al. RAF1 rearrangements are common in pancreatic acinar cell carcinomas. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 32358589 DOI: 10.1038/s41379-020-0545-9 |
0.21 |
|
| 2007 |
Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, Warren BF, Piris J, Roncador G, Fox SB, Banham AH, Cerundolo V. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients Cancer Immunity : a Journal of the Academy of Cancer Immunology. 7: 7. PMID 17388261 |
0.21 |
|
| 2016 |
Hendry SA, Farnsworth RH, Solomon B, Achen MG, Stacker SA, Fox SB. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. Frontiers in Immunology. 7: 621. PMID 28066431 DOI: 10.3389/fimmu.2016.00621 |
0.21 |
|
| 2012 |
Deb S, Zhang X, George J, Degoutin J, Takano E, Fox S, Bowtell D, Harvey K. 19. Yes-associated protein (YAP), regulated by the salvador-warts-hippo (SWH) pathway, is an ovarian cancer oncogene Pathology. 44: S110. DOI: 10.1016/S0031-3025(16)32911-7 |
0.207 |
|
| 2022 |
Winship AL, Alesi LR, Sant S, Stringer JM, Cantavenera A, Hegarty T, Requesens CL, Liew SH, Sarma U, Griffiths MJ, Zerafa N, Fox SB, Brown E, Caramia F, Zareie P, et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nature Cancer. 3: 1-13. PMID 36008687 DOI: 10.1038/s43018-022-00413-x |
0.207 |
|
| 2021 |
Lau LMS, Mayoh C, Xie J, Barahona P, MacKenzie KL, Wong M, Kamili A, Tsoli M, Failes TW, Kumar A, Mould EVA, Gifford A, Chow SO, Pinese M, Fletcher JI, ... ... Fox SB, et al. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. Embo Molecular Medicine. e14608. PMID 34927798 DOI: 10.15252/emmm.202114608 |
0.206 |
|
| 2012 |
Wolyniec K, Shortt J, de Stanchina E, Levav-Cohen Y, Alsheich-Bartok O, Louria-Hayon I, Corneille V, Kumar B, Woods SJ, Opat S, Johnstone RW, Scott CL, Segal D, Pandolfi PP, Fox S, et al. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood. 120: 822-32. PMID 22689861 DOI: 10.1182/Blood-2011-10-387647 |
0.205 |
|
| 2010 |
Rischin D, Young RJ, Fisher R, Fox SB, Le Q, Peters LJ, Solomon B, Choi J, O'Sullivan B, Kenny LM, McArthur GA. Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial Journal of Clinical Oncology. 28: 4142-4148. PMID 20697079 DOI: 10.1200/Jco.2010.29.2904 |
0.204 |
|
| 2015 |
Scott CL, Topp M, Hadley AM, Heong V, Harrell MI, McNally O, Fox SB, Lodhia K, Haluska P, Bowtell D, Swisher EM, Wakefield M. The use of patient-derived xenograft models for prioritizing therapeutic targets. Journal of Clinical Oncology. 33: 5579-5579. DOI: 10.1200/Jco.2015.33.15_Suppl.5579 |
0.204 |
|
| 2020 |
McEvoy CR, Holliday H, Thio N, Mitchell C, Choong DY, Yellapu B, Leong HS, Xu H, Lade S, Browning J, Takano EA, Byrne DJ, Gill AJ, Duong CP, Li J, ... ... Fox SB, et al. A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. Laboratory Investigation; a Journal of Technical Methods and Pathology. 101: 26-37. PMID 32873880 DOI: 10.1038/s41374-020-00484-3 |
0.203 |
|
| 2012 |
McArthur GA, Young RJ, Sheppard KE, Mar V, Waldeck K, Fox SB, Kelleher FC, Liu W, Dobrovic A, Pearson R, Kelly J, Christensen JG, Randolph S. Clinical significance of genomic alterations of the CDK4-pathway and sensitivity to the CDK4 inhibitor PD 0332991 in melanoma. Journal of Clinical Oncology. 30: 8520-8520. DOI: 10.1200/JCO.2012.30.15_SUPPL.8520 |
0.203 |
|
| 2020 |
Kharat SS, Ding X, Swaminathan D, Suresh A, Singh M, Sengodan SK, Burkett S, Marks H, Pamala C, He Y, Fox SD, Buehler EC, Muegge K, Martin SE, Sharan SK. Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability. Science Signaling. 13. PMID 32817374 DOI: 10.1126/Scisignal.Aba8091 |
0.203 |
|
| 2014 |
Young RJ, Waldeck K, Martin C, Foo JH, Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, Fox SB, Dutton-Regester K, Hayward NK, Jene N, Dobrovic A, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell & Melanoma Research. 27: 590-600. PMID 24495407 DOI: 10.1111/pcmr.12228 |
0.203 |
|
| 2020 |
Prall OWJ, McEvoy CRE, Byrne DJ, Iravani A, Browning J, Choong DY, Yellapu B, O'Haire S, Smith K, Luen SJ, Mitchell PLR, Desai J, Fox SB, Fellowes A, Xu H. A Malignant Neoplasm From the Jejunum With a Fusion and 26-Year Survival History. International Journal of Surgical Pathology. 1066896919900548. PMID 31931637 DOI: 10.1177/1066896919900548 |
0.203 |
|
| 2010 |
Solomon BJ, Young RJ, Fisher R, Fox SB, McArthur GA, Rischin D. Relationship between epidermal growth factor receptor (EGFR) gene copy number, p16 status, and outcome in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Journal of Clinical Oncology. 28: 5528-5528. DOI: 10.1200/JCO.2010.28.15_SUPPL.5528 |
0.199 |
|
| 2015 |
Rakha EA, Badve S, Eusebi V, Reis-Filho JS, Fox SB, Dabbs DJ, Decker T, Hodi Z, Ichihara S, Lee AH, Palacios J, Richardson AL, Vincent-Salomon A, Schmitt FC, Tan PH, et al. Breast lesions of uncertain malignant nature and limited metastatic potential: Proposals to improve their recognition and clinical management. Histopathology. PMID 26348644 DOI: 10.1111/his.12861 |
0.198 |
|
| 2011 |
Young RJ, Rischin D, Fisher R, McArthur GA, Fox SB, Peters LJ, Corry J, Lim A, Waldeck K, Solomon B. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 1230-7. PMID 21467228 DOI: 10.1158/1055-9965.EPI-10-1262 |
0.198 |
|
| 2017 |
Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, ... ... Fox SB, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology. PMID 28777143 DOI: 10.1097/Pap.0000000000000161 |
0.198 |
|
| 2014 |
Xu H, Yan Y, Deb S, Rangasamy D, Germann M, Malaterre J, Eder NC, Ward RL, Hawkins NJ, Tothill RW, Chen L, Mortensen NJ, Fox SB, McKay MJ, Ramsay RG. Cohesin Rad21 mediates loss of heterozygosity and is upregulated via Wnt promoting transcriptional dysregulation in gastrointestinal tumors. Cell Reports. 9: 1781-97. PMID 25464844 DOI: 10.1016/j.celrep.2014.10.059 |
0.197 |
|
| 2014 |
Zhang X, George J, Deb S, Degoutin J, Takano E, Fox S, Study group A, Bowtell D, Harvey K. 571: The Hippo pathway gene, YAP, is an oncogene in ovarian cancer European Journal of Cancer. 50: S137. DOI: 10.1016/S0959-8049(14)50506-0 |
0.197 |
|
| 2002 |
Rodins K, Cheale M, Coleman N, Fox SB. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1075-81. PMID 11948116 |
0.197 |
|
| 2014 |
Kumarasinghe MP, de Boer WB, Khor TS, Ooi EM, Jene N, Jayasinghe S, Fox SB. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio? Pathology. 46: 184-7. PMID 24614718 DOI: 10.1097/PAT.0000000000000075 |
0.195 |
|
| 2015 |
Thomas DM, Fox S, Lorgelly PK, Ashley D, Richardson G, Lipton L, Parisot JP, Lucas M, McNeil J. Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. Drug Discovery Today. PMID 26494144 DOI: 10.1016/j.drudis.2015.10.009 |
0.192 |
|
| 2008 |
Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting Bmc Research Notes. 1. DOI: 10.1186/1756-0500-1-14 |
0.192 |
|
| 2019 |
Issaq SH, Mendoza A, Fox SD, Helman LJ. Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth. Oncogenesis. 8: 20. PMID 30808861 DOI: 10.1038/s41389-019-0129-z |
0.189 |
|
| 2018 |
Blombery P, Thompson E, Ryland GL, Joyce R, Byrne DJ, Khoo C, Lade S, Hertzberg M, Hapgood G, Marlton P, Deva A, Lindeman G, Fox S, Westerman D, Prince M. Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget. 9: 36126-36136. PMID 30546832 DOI: 10.18632/oncotarget.26308 |
0.187 |
|
| 2011 |
Martin BP, Frew AJ, Bots M, Fox S, Long F, Takeda K, Yagita H, Atadja P, Smyth MJ, Johnstone RW. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. International Journal of Cancer. Journal International Du Cancer. 128: 2735-47. PMID 20715169 DOI: 10.1002/ijc.25594 |
0.186 |
|
| 2011 |
Issaq HJ, Fox SD, Chan KC, Veenstra TD. Global proteomics and metabolomics in cancer biomarker discovery. Journal of Separation Science. 34: 3484-92. PMID 22102289 DOI: 10.1002/jssc.201100528 |
0.185 |
|
| 2013 |
Koutros S, Meyer TE, Fox SD, Issaq HJ, Veenstra TD, Huang WY, Yu K, Albanes D, Chu LW, Andriole G, Hoover RN, Hsing AW, Berndt SI. Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis. 34: 2281-5. PMID 23698636 DOI: 10.1093/Carcin/Bgt176 |
0.185 |
|
| 2018 |
Solomon B, Young RJ, Bressel M, Urban D, Hendry S, Thai A, Angel C, Haddad A, Kowanetz M, Fua T, Corry J, Fox S, Rischin D. Prognostic significance of PD-L1+ and CD8+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. Cancer Immunology Research. PMID 29378694 DOI: 10.1158/2326-6066.CIR-17-0299 |
0.185 |
|
| 2017 |
Soo R, Lim J, Asuncion BR, Fazreen Z, Herrera M, Omar F, Seet JE, Bryne D, Hendry S, Fox S, Soong R. P2.01-027 A Comparison of Five Different Immunohistochemistry Assays for Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer Samples Journal of Thoracic Oncology. 12: S801. DOI: 10.1016/J.JTHO.2016.11.1079 |
0.184 |
|
| 2008 |
ZALCBERG JR, DESAI J, MANN B, FOX S, GOLDSTEIN D, MCARTHUR G, CLARK M, YIP D. Consensus approaches to best practice management of gastrointestinal stromal tumors Asia-Pacific Journal of Clinical Oncology. 4: 188-198. DOI: 10.1111/j.1743-7563.2008.00218.x |
0.181 |
|
| 2023 |
McEvoy CR, Holliday H, Thio N, Mitchell C, Choong DY, Yellapu B, Leong HS, Xu H, Lade S, Browning J, Takano EA, Byrne DJ, Gill AJ, Duong CP, Li J, ... ... Fox SB, et al. A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. Laboratory Investigation; a Journal of Technical Methods and Pathology. 101: 26-37. PMID 36775461 DOI: 10.1038/s41374-020-00484-3 |
0.181 |
|
| 2022 |
Fox SB, Webster F, Chen CJ, Chua B, Collins L, Foschini MP, Bruce Mann G, Millar E, Pinder SE, Rakha E, Shaaban A, Tan BY, Tse G, Watson P, Tan PH. Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology. PMID 35869801 DOI: 10.1111/his.14725 |
0.179 |
|
| 2007 |
Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2281-9. PMID 17404113 DOI: 10.1158/1078-0432.Ccr-06-2570 |
0.179 |
|
| 2015 |
Rogers TM, Russell PA, Wright G, Wainer Z, Pang JM, Henricksen LA, Singh S, Stanislaw S, Grille J, Roberts E, Solomon B, Fox SB. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 611-8. PMID 25789833 DOI: 10.1097/JTO.0000000000000465 |
0.178 |
|
| 2006 |
Nikitenko LL, Blucher N, Fox SB, Bicknell R, Smith DM, Rees MC. Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. Journal of Cell Science. 119: 910-22. PMID 16495482 DOI: 10.1242/jcs.02783 |
0.178 |
|
| 2014 |
Deb S, Fox SB. Molecular profiling in colorectal cancer: current state of play and future directions Colorectal Cancer. 3: 41-56. DOI: 10.2217/CRC.13.82 |
0.178 |
|
| 2017 |
Tan L, Alexander M, Officer A, MacManus M, Mileshkin L, Jennens R, Herath D, de Boer R, Fox SB, Ball D, Solomon B. Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC). Internal Medicine Journal. PMID 28544061 DOI: 10.1111/imj.13491 |
0.177 |
|
| 2020 |
Itchins M, Lau B, Hudson AL, Westman H, Xia CY, Hayes SA, Howell VM, Rodriguez M, Cooper W, Wei H, Buckland M, Li BT, Li M, Rathi V, Fox SB, et al. ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. The Oncologist. PMID 32558067 DOI: 10.1634/theoncologist.2020-0075 |
0.176 |
|
| 2023 |
van Mourik A, Tonkin-Hill G, O'Farrell J, Waller S, Tan L, Tothill RW, Bowtell D, Fox S, Fellowes A, Fedele C, Schofield P, Sivakumaran T, Wong HL, Mileshkin L. Six-year experience of Australia's first dedicated cancer of unknown primary clinic. British Journal of Cancer. PMID 37225894 DOI: 10.1038/s41416-023-02254-6 |
0.174 |
|
| 2014 |
Scott RJ, Fox SB, Desai J, Grieu F, Amanuel B, Garrett K, Harraway J, Cheetham G, Pattle N, Haddad A, Byron K, Rudzki B, Waring P, Iacopetta B. KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at? Asia-Pacific Journal of Clinical Oncology. 10: 261-5. PMID 24811330 DOI: 10.1111/ajco.12201 |
0.173 |
|
| 2014 |
Cooper W, Fox S, O'Toole S, Morey A, Frances G, Pavlakis N, O'Byrne K, Dettrick A, Leong T, Rathi V, Spagnolo D, Hemmings C, Singh M, Moffat D, Tsao MS, et al. National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology. 10: 11-7. PMID 24673736 DOI: 10.1111/Ajco.12190 |
0.172 |
|
| 2015 |
Wong SQ, Fellowes A, Doig K, Ellul J, Bosma TJ, Irwin D, Vedururu R, Tan AY, Weiss J, Chan KS, Lucas M, Thomas DM, Dobrovic A, Parisot JP, Fox SB. Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. British Journal of Cancer. 112: 1411-20. PMID 25742471 DOI: 10.1038/bjc.2015.80 |
0.171 |
|
| 2020 |
Williams SG, Aw Yeang HX, Mitchell C, Caramia F, Byrne DJ, Fox SB, Haupt S, Schittenhelm RB, Neeson PJ, Haupt Y, Keam SP. Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. Bmc Urology. 20: 171. PMID 33115461 DOI: 10.1186/s12894-020-00738-8 |
0.171 |
|
| 2009 |
Rischin D, Young R, Fisher R, Fox S, Le Q, Peters L, Choi J, O'Sullivan B, Giralt J, McArthur G. Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6004. PMID 27962411 DOI: 10.1200/jco.2009.27.15_suppl.6004 |
0.171 |
|
| 2021 |
Prall OWJ, Browning J, Nastevski V, Caporarello S, Bates B, Hewitt CA, Arenas A, Lamb G, Howlett K, Arnolda R, Adeloju R, Stuart S, Xu H, Fellowes A, Fox SB. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance. Pathology. PMID 34635319 DOI: 10.1016/j.pathol.2021.07.006 |
0.171 |
|
| 2016 |
Sato T, Paquet-Fifield S, Harris NC, Roufail S, Turner DJ, Yuan Y, Zhang YF, Fox SB, Hibbs ML, Wilkinson-Berka JL, Williams RA, Stacker SA, Sly PD, Achen MG. Vegf-d promotes pulmonary oedema in hyperoxic acute lung injury. The Journal of Pathology. PMID 26924464 DOI: 10.1002/path.4708 |
0.17 |
|
| 2022 |
Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, ... ... Fox SB, et al. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102108. PMID 35263119 DOI: 10.1200/JCO.21.02108 |
0.17 |
|
| 2020 |
Liu X, Lu Y, Chen Z, Liu X, Hu W, Zheng L, Chen Y, Kurie JM, Shi M, Mustachio LM, Andresson T, Fox S, Roszik J, Kawakami M, Freemantle S, et al. The Ubiquitin Specific Protease USP18 Promotes Lipolysis, Fatty Acid Oxidation and Lung Cancer Growth. Molecular Cancer Research : McR. PMID 33380466 DOI: 10.1158/1541-7786.MCR-20-0579 |
0.17 |
|
| 2010 |
Huang KT, Dobrovic A, Yan M, Karim RZ, Lee CS, Lakhani SR, Fox SB. DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Research and Treatment. 124: 555-65. PMID 20563638 DOI: 10.1007/s10549-010-0970-4 |
0.17 |
|
| 2012 |
Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. The American Journal of Surgical Pathology. 36: 577-82. PMID 22314190 DOI: 10.1097/PAS.0b013e318244adbb |
0.168 |
|
| 2013 |
Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, Wright GM, Wainer Z, Horvath LG, Boyer M, McCaughan B, Kohonen-Corish MR, Fox S, Cooper WA, Solomon B. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 1545-53. PMID 23743928 DOI: 10.1038/modpathol.2013.87 |
0.167 |
|
| 2014 |
Siva S, Deb S, Young R, Bressel M, Mileshkin L, Rischin D, Bernshaw D, Fox S, Hicks R, Narayan K. OC-0364: Impact of imaging and pathological biomarkers on survival after chemoradiation of locally advanced cervical cancer Radiotherapy and Oncology. 111: S140-S141. DOI: 10.1016/S0167-8140(15)30469-2 |
0.167 |
|
| 2015 |
Parisot JP, Thorne H, Fellowes A, Doig K, Lucas M, McNeil JJ, Doble B, Dobrovic A, John T, James PA, Lipton L, Ashley D, Hayes T, McMurrick P, Richardson G, ... ... Fox SB, et al. "Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. Journal of Personalized Medicine. 5: 354-69. PMID 26529019 DOI: 10.3390/jpm5040354 |
0.166 |
|
| 2012 |
Willems-Jones A, Kavanagh L, Clouston D, Bolton D, Fox S, Thorne H. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer. Bju International. 110: E1181-6. PMID 23035815 DOI: 10.1111/j.1464-410X.2012.11519.x |
0.166 |
|
| 2015 |
Deb S, Xu H, Tuynman JB, George J, Yan Y, Li J, Ward R, Mortensen N, Hawkins N, McKay M, Ramsay RG, Fox SB. RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in kras mutant colorectal carcinomas Pathology. 47: S53-S54. DOI: 10.1097/01.PAT.0000461457.19279.A3 |
0.164 |
|
| 2012 |
Deb S, Xu H, Clouston D, Ramsay R, Fox S. 20. RAD21 overexpression is frequently observed in prostate cancer Pathology. 44: S110-S111. DOI: 10.1016/S0031-3025(16)32912-9 |
0.164 |
|
| 2014 |
Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner GC, Ngan SY, Chander S, Powell GJ, Herschtal A, Te Marvelde L, Desai J, Choong PF, Stacker SA, Achen MG, ... ... Fox S, et al. A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. British Journal of Cancer. 111: 2254-61. PMID 25321190 DOI: 10.1038/bjc.2014.537 |
0.164 |
|
| 2023 |
Abdelmogod A, Papadopoulos L, Riordan S, Wong M, Weltman M, Lim R, McEvoy C, Fellowes A, Fox S, Bedő J, Penington J, Pham K, Hofmann O, Vissers JHA, Grimmond S, et al. A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review. Cancers. 15. PMID 37686662 DOI: 10.3390/cancers15174378 |
0.164 |
|
| 2012 |
Siva S, Bressel M, Hicks R, Bernshaw D, Gill S, Deb S, Fox S, Narayan K. Routine Follow-up Rarely Detects Disease Recurrence After a Complete Response on FDG-PET in Patients With Locally Advanced Cervical Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S20. DOI: 10.1016/J.IJROBP.2012.07.056 |
0.163 |
|
| 2009 |
Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Wei QL, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox S, Scott RJ, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting Journal of Molecular Diagnostics. 11: 543-552. PMID 19815694 DOI: 10.2353/jmoldx.2009.090057 |
0.162 |
|
| 2013 |
Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, Fellowes A, Semple T, Fox S, Byron K, Kowalczyk A, Thomas D, Schofield P, Bowtell DD. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. The Journal of Pathology. 231: 413-23. PMID 24037760 DOI: 10.1002/path.4251 |
0.162 |
|
| 2020 |
Velasco A, Tokat F, Bonde J, Trim N, Bauer E, Meeney A, de Leng W, Chong G, Dalstein V, Kis LL, Lorentzen JA, Tomić S, Thwaites K, Putzová M, Birnbaum A, ... ... Fox SB, et al. Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer. Virchows Archiv : An International Journal of Pathology. PMID 33170334 DOI: 10.1007/s00428-020-02962-x |
0.162 |
|
| 2022 |
McEvoy CR, Kee D, Prall OWJ, Clay TD, Scott C, Backhouse A, Fox SB, Fellowes AP, Xu H. MEK Inhibitor Therapy in Carcinomas With Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell Carcinoma. Jco Precision Oncology. 3: 1-2. PMID 35100731 DOI: 10.1200/PO.19.00159 |
0.161 |
|
| 2009 |
Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, Eden CG, Miller PD, Langley SE, Laing RW. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Research. 29: 1483-8. PMID 19443354 |
0.161 |
|
| 2020 |
Smith KM, O Haire S, Khuong-Quang DA, Markman B, Gan HK, Ekert PG, O'Byrne KJ, Millward M, Solomon BJ, Tran B, Scott CL, Kee D, McArthur GA, Fellowes A, Weerasuriya R, ... ... Fox SB, et al. Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts). Journal of Clinical Oncology. 38: 2033-2033. DOI: 10.1200/jco.2020.38.15_suppl.2033 |
0.16 |
|
| 2022 |
O'Haire S, Degeling K, Franchini F, Tran B, Luen SJ, Gaff C, Smith K, Fox S, Desai J, IJzerman M. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm. Targeted Oncology. PMID 36063280 DOI: 10.1007/s11523-022-00910-0 |
0.16 |
|
| 2014 |
James PA, Petelin L, Campbell I, Dawkins H, Fox S, Hiller J, Kirk J, Lindeman G, Macrae F, Mascarenhas L, McGaughran J, Meiser B, Morrow A, Nichols C, Pachter N, et al. The inherited cancer connect (iccon) mutation-carrier database Asia-Pacific Journal of Clinical Oncology. 10: 167-168. DOI: 10.1111/Ajco.12305 |
0.16 |
|
| 2012 |
Chan A, Lambeth L, Horvath L, Kench J, Williams E, Haupt S, Fox S, Haupt Y. 103 Defining the Involvement of the E5AP-PML Axis in Prostate Cancer European Journal of Cancer. 48: S25. DOI: 10.1016/S0959-8049(12)70807-9 |
0.16 |
|
| 2003 |
Beale G, Hollins AJ, Benboubetra M, Sohail M, Fox SP, Benter I, Akhtar S. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessible region using the same delivery system. Journal of Drug Targeting. 11: 449-56. PMID 15203934 DOI: 10.1080/1061186042000207039 |
0.158 |
|
| 2005 |
Morrin H, Gunningham S, Currie M, Dachs G, Fox S, Robinson B. The Christchurch Tissue Bank to support cancer research. The New Zealand Medical Journal. 118: U1735. PMID 16286947 |
0.158 |
|
| 2015 |
Gan C, Love C, Beshay V, Macrae F, Fox S, Waring P, Taylor G. Applicability of next generation sequencing technology in microsatellite instability testing. Genes. 6: 46-59. PMID 25685876 DOI: 10.3390/genes6010046 |
0.157 |
|
| 2022 |
Yu SL, Hsiao YJ, Cooper WA, Choi YL, Avilés-Salas A, Chou TY, Coudry R, Raskin GA, Fox SB, Huang CC, Jeon YK, Ko YH, Ku WH, Kwon GY, Leslie C, et al. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. Pathology. PMID 36319485 DOI: 10.1016/j.pathol.2022.07.016 |
0.156 |
|
| 2009 |
Hoh I, Thorne H, Willems A, Li J, Hopper J, Fox S, Sambrook J, Bolton D. POD-02.07: BRCA2 Mutation Confers an Increased Risk of Aggressive Prostate Cancer in Australia and New Zealand Urology. 74: S6. DOI: 10.1016/J.UROLOGY.2009.07.1201 |
0.155 |
|
| 2017 |
John T, Bowden JJ, Clarke S, Fox SB, Garrett K, Horwood K, Karapetis CS. Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology. PMID 28699260 DOI: 10.1111/ajco.12699 |
0.154 |
|
| 2015 |
Flynn A, Benn D, Clifton-Bligh R, Robinson B, Trainer AH, James P, Hogg A, Waldeck K, George J, Li J, Fox SB, Gill AJ, McArthur G, Hicks RJ, Tothill RW. The genomic landscape of phaeochromocytoma. The Journal of Pathology. 236: 78-89. PMID 25545346 DOI: 10.1002/path.4503 |
0.153 |
|
| 2003 |
Haas NB, Giantonio BJ, Litwin S, Minniti CJ, Fox S, Yeslow G, Reilly R, Nahum K, Greenberg R, Halbherr T, Hudes GR. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. Cancer. 98: 1837-41. PMID 14584064 DOI: 10.1002/cncr.11734 |
0.152 |
|
| 2014 |
Deb S, Xu H, Tuynman J, George J, Yan Y, Li J, Ward RL, Mortensen N, Hawkins NJ, McKay MJ, Ramsay RG, Fox SB. RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. British Journal of Cancer. 110: 1606-13. PMID 24548858 DOI: 10.1038/bjc.2014.31 |
0.151 |
|
| 2014 |
Yip D, Zalcberg J, Ackland S, Barbour AP, Desai J, Fox S, Kotasek D, McArthur G, Smithers BM. Controversies in the management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology. 10: 216-27. PMID 24673914 DOI: 10.1111/ajco.12187 |
0.151 |
|
| 2020 |
McEvoy CR, Fox SB, Prall OWJ. Emerging entities in NUTM1-rearranged neoplasms. Genes, Chromosomes & Cancer. PMID 32060986 DOI: 10.1002/gcc.22838 |
0.15 |
|
| 2012 |
Lim AM, Young RJ, Collins M, Fox SB, McArthur GA, Corry J, Peters L, Rischin D, Solomon B. Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. Oral Oncology. 48: 698-702. PMID 22410096 DOI: 10.1016/j.oraloncology.2012.02.014 |
0.149 |
|
| 2020 |
Howland RE, Deziel NC, Bentley GR, Booth M, Choudhury OA, Hofmann JN, Hoover RN, Katki HA, Trabert B, Fox SD, Troisi R, Houghton LC. Assessing Endogenous and Exogenous Hormone Exposures and Breast Development in a Migrant Study of Bangladeshi and British Girls. International Journal of Environmental Research and Public Health. 17. PMID 32069802 DOI: 10.3390/Ijerph17041185 |
0.148 |
|
| 2007 |
Sooriakumaran P, Laing R, Macanas-Pirard P, Coley H, Fox S, Bucca G, Lovell D, Henderson A, Smith C, Eden C, Miller P, Langley S. 1151: A Blinded, Randomized Controlled Trial of Neo-Adjuvant Celecoxib in Patients with CT1-2 Prostate Cancer Journal of Urology. 177: 380-380. DOI: 10.1016/S0022-5347(18)31365-X |
0.147 |
|
| 2012 |
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet. Oncology. 13: 1011-9. PMID 22954507 DOI: 10.1016/S1470-2045(12)70344-3 |
0.147 |
|
| 2015 |
Ashley DM, Gupta S, Tran T, Wei L, Lorgelly PK, Thomas DM, Fox SB, Venkatesh S. Machine-learning prediction of cancer survival: A prospective study examining the impact of combining clinical and genomic data. Journal of Clinical Oncology. 33: 6521-6521. DOI: 10.1200/JCO.2015.33.15_SUPPL.6521 |
0.145 |
|
| 2021 |
Mead S, Lucas M, Pang JM, Fellowes A, Harraway J, Svobodova S, Amanuel B, Fox S. EGFR mutation profile in Australian patients with non-small cell lung cancer. Pathology. PMID 33966854 DOI: 10.1016/j.pathol.2021.01.017 |
0.145 |
|
| 2022 |
Markham JF, Fellowes AP, Green T, Leal JL, Legaie R, Cullerne D, Morris T, John T, Solomon B, Fox SB. Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. British Journal of Cancer. PMID 36572732 DOI: 10.1038/s41416-022-02105-w |
0.145 |
|
| 2010 |
Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prevention Research (Philadelphia, Pa.). 3: 1066-76. PMID 20810672 DOI: 10.1158/1940-6207.CAPR-10-0055 |
0.142 |
|
| 2012 |
Siva S, Deb S, Bressel M, Gill S, Fox S, Hicks R, Narayan K. OC-0125 LONG-TERM OUTCOMES OF A PROSPECTIVE STUDY OF POST-THERAPY PET AFTER CHEMORADIATION OF CERVICAL CANCER Radiotherapy and Oncology. 103: S49. DOI: 10.1016/S0167-8140(12)70464-4 |
0.142 |
|
| 2012 |
Alamgeer M, Rogers T, Fox SB, Solomon B. Crizotinib for the treatment of non-small-cell lung cancer withALKgene rearrangements Clinical Investigation. 2: 895-907. DOI: 10.4155/CLI.12.84 |
0.141 |
|
| 2015 |
Scott R, Dooley S, Lewis W, Meldrum C, Pockney P, Draganic B, Smith S, Jones F, Hewitt C, Phillimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, ... ... Fox S, et al. P-273 Concordance of RAS mutation status in CRC patients by comparison of results from circulating tumour DNA and tissue-based testing Annals of Oncology. 26: iv80. DOI: 10.1093/ANNONC/MDV233.270 |
0.141 |
|
| 2007 |
Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ, DeFazio A, Fox SB, Brenton JD, Bowtell DD, Dobrovic A. High resolution melting for mutation scanning of TP53 exons 5-8. Bmc Cancer. 7: 168. PMID 17764544 DOI: 10.1186/1471-2407-7-168 |
0.139 |
|
| 2018 |
McEvoy CR, Koe L, Choong DY, Leong HS, Xu H, Karikios D, Plew JD, Prall OW, Fellowes AP, Fox SB. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. Npj Precision Oncology. 2: 9. PMID 29872718 DOI: 10.1038/s41698-018-0053-2 |
0.138 |
|
| 2016 |
Lewin J, Vis DJ, Lawler M, Liao R, Mao M, Teh BT, Sellers W, Ward R, Camargo AA, Andre F, Schilsky R, Lacombe D, Shibata T, Fox S, Tourneau CL, et al. Abstract 1832: Large variations in clinical and ethical aspects of genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey Cancer Research. 76: 1832-1832. DOI: 10.1158/1538-7445.Am2016-1832 |
0.137 |
|
| 2017 |
Najdawi F, Crook A, Maidens J, McEvoy C, Fellowes A, Pickett J, Ho M, Nevell D, McIlroy K, Sheen A, Sioson L, Ahadi M, Turchini J, Clarkson A, Hogg R, ... ... Fox SB, et al. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy. Pathology. PMID 28669579 DOI: 10.1016/j.pathol.2017.05.004 |
0.137 |
|
| 2018 |
Soo RA, Yun Lim JS, Asuncion BR, Fazreen Z, Herrera MC, Mohd Omar MF, Diem Phuong NH, Seet JE, Amanuel B, Iacopetta B, Byrne D, Hendry S, Fox S, Soong R. Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples. Oncotarget. 9: 6841-6851. PMID 29467933 DOI: 10.18632/oncotarget.23827 |
0.136 |
|
| 2016 |
Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, Draganic B, Smith S, Hewitt C, Philimore H, Lucas A, Shi E, Namdarian K, Chan T, Acosta D, ... ... Fox SB, et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Molecular Oncology. PMID 28106345 DOI: 10.1002/1878-0261.12023 |
0.136 |
|
| 2003 |
Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Molecular Cancer Therapeutics. 2: 409-17. PMID 12700285 |
0.133 |
|
| 2013 |
Malik L, Hemmings C, Beshay V, Fox S, Yip D. Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missence mutations. Pathology. 45: 604-6. PMID 24018806 DOI: 10.1097/PAT.0b013e3283653792 |
0.131 |
|
| 2018 |
Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, ... ... Fox SB, et al. Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine. PMID 30135555 DOI: 10.1038/s41591-018-0176-6 |
0.128 |
|
| 2016 |
Wong SQ, Scott R, Fox SB. KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future Colorectal Cancer. 5: 73-80. DOI: 10.2217/CRC-2015-0009 |
0.126 |
|
| 2023 |
Park JE, Kirsch K, Lee H, Oliva P, Ahn JI, Ravishankar H, Zeng Y, Fox SD, Kirby SA, Badhwar P, Andresson T, Jacobson KA, Lee KS. Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition. Proceedings of the National Academy of Sciences of the United States of America. 120: e2305037120. PMID 37603740 DOI: 10.1073/pnas.2305037120 |
0.122 |
|
| 2008 |
Takano EA, Mitchell G, Fox SB, Dobrovic A. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. Bmc Cancer. 8: 59. PMID 18298804 DOI: 10.1186/1471-2407-8-59 |
0.122 |
|
| 2015 |
Doig K, Papenfuss AT, Fox S. Clinical cancer genomic analysis: data engineering required. The Lancet. Oncology. 16: 1015-7. PMID 26370340 DOI: 10.1016/S1470-2045(15)00195-3 |
0.122 |
|
| 1995 |
Rosenberg WMC, Jackson DG, Trowell JM, Bell JI, Prince C, Chapman RW, Jewel DP, Kaklamanis L, Fox SB, Simmons DL. Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease The Lancet. 345: 1205-1209. PMID 7537840 DOI: 10.1016/S0140-6736(95)91991-0 |
0.121 |
|
| 2020 |
Conduit C, Luen S, Xu H, Byrne D, Fox S, Desai J, Hamilton A. Using Genomic Sequencing to Explain an Exceptional Response to Therapy in a Malignant Phyllodes Tumor. Jco Precision Oncology. 4: 1263-1266. PMID 35050785 DOI: 10.1200/PO.20.00305 |
0.121 |
|
| 2024 |
Andrew EC, Lewin J, Desai J, Orme L, Hamilton A, Bae S, Zhu W, Nicolson S, Varghese LN, Mitchell CB, Vissers JHA, Xu H, Grimmond SM, Fox SB, Luen SJ. Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma. Journal of Personalized Medicine. 14. PMID 38392562 DOI: 10.3390/jpm14020128 |
0.12 |
|
| 2012 |
Wolyniec K, Shortt J, Opat S, Johnstone R, Scott C, Fox S, Strasser A, Haupt S, Haupt Y. 178 E6AP Ubiquitin Ligase Regulates PML-induced Senescence in Myc-driven Lymphomagenesis European Journal of Cancer. 48: S43. DOI: 10.1016/S0959-8049(12)70877-8 |
0.119 |
|
| 2015 |
Khoo C, Rogers TM, Fellowes A, Bell A, Fox S. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Translational Lung Cancer Research. 4: 126-41. PMID 25870795 DOI: 10.3978/j.issn.2218-6751.2015.01.10 |
0.119 |
|
| 2019 |
Hendry S, Byrne DJ, Christie M, Steinfort DP, Irving LB, Wagner CA, Ellwood T, Cooper WA, Fox SB. Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell block specimens. Cytopathology : Official Journal of the British Society For Clinical Cytology. PMID 31808243 DOI: 10.1111/cyt.12795 |
0.119 |
|
| 2017 |
Rogers TM, Arnau GM, Ryland GL, Huang S, Lira ME, Emmanuel Y, Perez OD, Irwin D, Fellowes AP, Wong SQ, Fox SB. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Scientific Reports. 7: 42259. PMID 28181564 DOI: 10.1038/srep42259 |
0.118 |
|
| 2014 |
Pang J, Takano E, Byrne D, Deb S, Jene N, Boulghourjian A, Holliday A, Millar E, Lee S, O’Toole S, Dobrovic A, Fox SB. Candidate methylation profiling of ductal carcinoma in situ and its relationship to phenotype Pathology. 46: S76. DOI: 10.1097/01.PAT.0000443597.70603.41 |
0.114 |
|
| 2002 |
Groves FD, Issaq H, Fox S, Jeffrey AM, Whysner J, Zhang L, You WC, Fraumeni JF. N-nitroso compounds and mutagens in Chinese fermented (sour) corn pancakes. Journal of Aoac International. 85: 1052-6. PMID 12374403 |
0.114 |
|
| 2013 |
Halford MM, Macheda ML, Parish CL, Takano EA, Fox S, Layton D, Nice E, Stacker SA. A fully human inhibitory monoclonal antibody to the Wnt receptor RYK. Plos One. 8: e75447. PMID 24058687 DOI: 10.1371/Journal.Pone.0075447 |
0.11 |
|
| 2023 |
Pang JB, Byrne DJ, Bergin ART, Caramia F, Loi S, Gorringe KL, Fox SB. Spatial transcriptomics and the anatomical pathologist: Molecular meets morphology. Histopathology. PMID 37991396 DOI: 10.1111/his.15093 |
0.109 |
|
| 2010 |
Krakauer T, Buckley M, Issaq HJ, Fox SD. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrobial Agents and Chemotherapy. 54: 1125-31. PMID 20086156 DOI: 10.1128/AAC.01015-09 |
0.108 |
|
| 2021 |
Pang JB, Castles B, Byrne DJ, Button P, Hendry S, Lakhani SR, Sivasubramaniam V, Cooper WA, Armes J, Millar EKA, Raymond W, Roberts-Thomson S, Kumar B, Burr M, Selinger C, ... ... Fox SB, et al. SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. The American Journal of Surgical Pathology. PMID 34232604 DOI: 10.1097/PAS.0000000000001701 |
0.107 |
|
| 2018 |
Mascarenhas L, Shanley S, Mitchell G, Spurdle AB, Macrae F, Pachter N, Buchanan DD, Ward RL, Fox S, Duxbury E, Driessen R, Boussioutas A. Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providers. Asia-Pacific Journal of Clinical Oncology. PMID 30294856 DOI: 10.1111/ajco.13076 |
0.107 |
|
| 2005 |
Fox SR, Yap MX, Yap MG, Wang DI. Active hypothermic growth: a novel means for increasing total interferon-gamma production by Chinese-hamster ovary cells. Biotechnology and Applied Biochemistry. 41: 265-72. PMID 15504104 DOI: 10.1042/BA20040067 |
0.105 |
|
| 2017 |
Cooper WA, Russell PA, Cherian M, Duhig EE, Godbolt D, Jessup PJ, Khoo C, Leslie C, Mahar A, Moffat DF, Sivasubramaniam V, Faure C, Reznichenko A, Grattan A, Fox SB. Intra- and Inter-Observer Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28420726 DOI: 10.1158/1078-0432.CCR-17-0151 |
0.104 |
|
| 2017 |
Hendry S, Byrne DJ, Wright GM, Young RJ, Sturrock S, Cooper WA, Fox SB. Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29175115 DOI: 10.1016/j.jtho.2017.11.112 |
0.104 |
|
| 2022 |
Arnolda R, Howlett K, Chan T, Raleigh J, Hatzimihalis A, Bell A, Fellowes A, Sandhu S, McArthur GA, Fox SB, Dawson SJ, Hewitt C, Jones K, Wong SQ. Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA. Pathology. PMID 35618509 DOI: 10.1016/j.pathol.2022.02.010 |
0.103 |
|
| 2010 |
De Ravin SS, Zarember KA, Long-Priel D, Chan KC, Fox SD, Gallin JI, Kuhns DB, Malech HL. Tryptophan/kynurenine metabolism in human leukocytes is independent of superoxide and is fully maintained in chronic granulomatous disease. Blood. 116: 1755-60. PMID 20511543 DOI: 10.1182/blood-2009-07-233734 |
0.103 |
|
| 2023 |
Dall G, Vandenberg CJ, Nesic K, Ratnayake G, Zhu W, Vissers JHA, Bedő J, Penington J, Wakefield MJ, Kee D, Carmagnac A, Lim R, Shield-Artin K, Milesi B, Lobley A, ... ... Fox SB, et al. Targeting homologous recombination deficiency in uterine leiomyosarcoma. Journal of Experimental & Clinical Cancer Research : Cr. 42: 112. PMID 37143137 DOI: 10.1186/s13046-023-02687-0 |
0.102 |
|
| 2016 |
Doble B, John T, Thomas D, Fellowes A, Fox S, Lorgelly P. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer (Amsterdam, Netherlands). PMID 27316470 DOI: 10.1016/j.lungcan.2016.05.024 |
0.101 |
|
| 2021 |
Mweempwa A, Xu H, Vissers JHA, Tothill RW, Pattison AD, Fellowes AP, Thomas DM, Richardson G, Hicks RJ, Grimmond SM, Fox SB, Luen SJ, Desai J, Solomon BJ. Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. Jco Precision Oncology. 5: 1160-1165. PMID 34994633 DOI: 10.1200/PO.21.00127 |
0.099 |
|
| 2022 |
White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Fox SB, Michael M, Ackland S. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping. Clinical Pharmacology and Therapeutics. PMID 35607723 DOI: 10.1002/cpt.2667 |
0.098 |
|
| 2021 |
Robertson SJ, Orme L, Teixeira R, Shamassi M, Newell F, Patch AM, Yeh I, Gard G, Wilmott J, Jackett L, LeBoit P, Fellowes A, MacArthur G, Fox S, Hayward NK, et al. Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. Jama Dermatology. PMID 34076666 DOI: 10.1001/jamadermatol.2021.0025 |
0.098 |
|
| 2005 |
Fox SR, Tan HK, Tan MC, Wong SC, Yap MG, Wang DI. A detailed understanding of the enhanced hypothermic productivity of interferon-gamma by Chinese-hamster ovary cells. Biotechnology and Applied Biochemistry. 41: 255-64. PMID 15504103 DOI: 10.1042/BA20040066 |
0.097 |
|
| 2008 |
Do H, Krypuy M, Mitchell PL, Fox SB, Dobrovic A. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies Bmc Cancer. 8. PMID 18495026 DOI: 10.1186/1471-2407-8-142 |
0.095 |
|
| 2013 |
Doble B, Harris A, Thomas DM, Fox S, Lorgelly P. Multiomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. Pharmacogenomics. 14: 1405-17. PMID 24024894 DOI: 10.2217/pgs.13.142 |
0.094 |
|
| 2019 |
McEvoy CR, Semple T, Yellapu B, Choong DY, Xu H, Mir Arnau G, Fellowes AP, Fox SB. Improved next-generation sequencing pre-capture library yields and sequencing parameters using on-bead PCR. Biotechniques. PMID 31825238 DOI: 10.2144/btn-2019-0059 |
0.093 |
|
| 2019 |
Markham J, Yerneni S, Ryland GL, Fellowes A, Thompson E, Fox S, Westerman DA, Dickinson M, Papenfuss A, Blombery P. Cnspectorx - Copy Number Assessment at a Genome Level from Targeted Sequence Data Optimized for Hematological Malignancy Blood. 134: 3378-3378. DOI: 10.1182/blood-2019-125471 |
0.092 |
|
| 2022 |
Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, John T, Devereux L, Donnelly PS, Hicks R, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, et al. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. Bmj Open. 12: e056708. PMID 36400733 DOI: 10.1136/bmjopen-2021-056708 |
0.091 |
|
| 2008 |
Read SW, Lempicki RA, Di Mascio M, Srinivasula S, Burke R, Sachau W, Bosche M, Adelsberger JW, Sereti I, Davey RT, Tavel JA, Huang CY, Issaq HJ, Fox SD, Lane H, et al. CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. The Journal of Infectious Diseases. 198: 843-50. PMID 18684102 DOI: 10.1086/591250 |
0.091 |
|
| 2018 |
Goswami C, Fox S, Holden M, Connor M, Leanord A, Evans TJ. Genetic analysis of invasive Escherichia coli in Scotland reveals determinants of healthcare-associated versus community-acquired infections. Microbial Genomics. PMID 29932391 DOI: 10.1099/mgen.0.000190 |
0.091 |
|
| 2017 |
Lam M, Tran B, Beck S, Tie J, Herath D, Whittle J, Kwan EM, Fox SB, Fellowes A, Ananda S, Lipton L, Gibbs P, Rosenthal MA, Desai J. Precision oncology using a clinician-directed, tailored approach to molecular profiling. Asia-Pacific Journal of Clinical Oncology. PMID 29083093 DOI: 10.1111/ajco.12787 |
0.09 |
|
| 2017 |
Doig KD, Fellowes A, Bell AH, Seleznev A, Ma D, Ellul J, Li J, Doyle MA, Thompson ER, Kumar A, Lara L, Vedururu R, Reid G, Conway T, Papenfuss AT, ... Fox SB, et al. PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories. Genome Medicine. 9: 38. PMID 28438193 DOI: 10.1186/s13073-017-0427-z |
0.09 |
|
| 1992 |
Fox SB, Cotton DW. Tubular apocrine adenoma and papillary eccrine adenoma. Entities or unity? The American Journal of Dermatopathology. 14: 149-54. PMID 1566975 DOI: 10.1097/00000372-199204000-00013 |
0.088 |
|
| 2005 |
Gilmore IR, Fox SP, Hollins AJ, Sohail M, Akhtar S. The design and exogenous delivery of siRNA for post-transcriptional gene silencing. Journal of Drug Targeting. 12: 315-40. PMID 15545082 DOI: 10.1080/10611860400006257 |
0.087 |
|
| 2013 |
Richter A, Grieu F, Carrello A, Amanuel B, Namdarian K, Rynska A, Lucas A, Michael V, Bell A, Fox SB, Hewitt CA, Do H, McArthur GA, Wong SQ, Dobrovic A, et al. A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Scientific Reports. 3: 1659. PMID 23584600 DOI: 10.1038/srep01659 |
0.087 |
|
| 2016 |
Pang JMB, Gorringe KL, Fox SB. Ductal carcinoma in situ - update on risk assessment and management Histopathology. 68: 96-109. DOI: 10.1111/his.12796 |
0.086 |
|
| 2019 |
Parthibane V, Acharya D, Srideshikan SM, Lin J, Myerscough DG, Abimannan T, Vijaykrishna N, Blankenberg D, Bondada L, Klarmann KD, Fox SD, Andresson T, Tessarollo L, Acharya U, Keller JR, et al. Sptlc1 is essential for myeloid differentiation and hematopoietic homeostasis. Blood Advances. 3: 3635-3649. PMID 31751474 DOI: 10.1182/Bloodadvances.2019000729 |
0.086 |
|
| 2006 |
Gilmore IR, Fox SP, Hollins AJ, Akhtar S. Delivery strategies for siRNA-mediated gene silencing. Current Drug Delivery. 3: 147-5. PMID 16611001 DOI: 10.2174/156720106776359159 |
0.085 |
|
| 2021 |
Shrimp JH, Jing Y, Gamage ST, Nelson KM, Han J, Bryson KM, Montgomery DC, Thomas JM, Nance KD, Sharma S, Fox SD, Andressen T, Sinclair WR, Wu H, Allali-Hassani A, et al. Remodelin Is a Cryptic Assay Interference Chemotype That Does Not Inhibit NAT10-Dependent Cytidine Acetylation. Acs Medicinal Chemistry Letters. 12: 887-892. PMID 34141066 DOI: 10.1021/acsmedchemlett.0c00193 |
0.083 |
|
| 2023 |
Rickard JA, Rogers TM, Westerman DA, Carolan C, Fox SB. Identification errors in medical research: Privacy at all costs? Contemporary Clinical Trials. 107206. PMID 37119991 DOI: 10.1016/j.cct.2023.107206 |
0.082 |
|
| 2013 |
Nachman RM, Fox SD, Golden WC, Sibinga E, Veenstra TD, Groopman JD, Lees PS. Urinary free bisphenol A and bisphenol A-glucuronide concentrations in newborns. The Journal of Pediatrics. 162: 870-2. PMID 23312693 DOI: 10.1016/J.Jpeds.2012.11.083 |
0.082 |
|
| 2016 |
Fox SJ, Fazil MH, Dhand C, Venkatesh M, Goh ET, Harini S, Eugene C, Lim RR, Ramakrishna S, Chaurasia SS, Beuerman RW, Verma CS, Verma NK, Loh XJ, Lakshminarayanan R. Insight into membrane selectivity of linear and branched polyethylenimines and their potential as biocides for advanced wound dressings. Acta Biomaterialia. PMID 27079762 DOI: 10.1016/j.actbio.2016.04.015 |
0.079 |
|
| 2011 |
Hondow HL, Fox SB, Mitchell G, Scott RJ, Beshay V, Wong SQ, Dobrovic A. A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. Bmc Cancer. 11: 265. PMID 21702907 DOI: 10.1186/1471-2407-11-265 |
0.077 |
|
| 2017 |
Fox SJ, Kannan S. Probing the dynamics of disorder. Progress in Biophysics and Molecular Biology. PMID 28554553 DOI: 10.1016/j.pbiomolbio.2017.05.008 |
0.076 |
|
| 2023 |
Hegi-Johnson F, Rudd SE, Wichmann CW, Akhurst T, Roselt P, Sursock S, Trinh J, John T, Devereux L, Donnelly PS, Hicks RJ, Scott AM, Steinfort D, Fox S, Blyth B, et al. PD-L1 PET imaging in patients with NSCLC: Preliminary results of the ImmunoPET Phase 0 study. International Journal of Radiation Oncology, Biology, Physics. PMID 37406824 DOI: 10.1016/j.ijrobp.2023.05.019 |
0.076 |
|
| 2004 |
Huang J, Fan T, Yan Q, Zhu H, Fox S, Issaq HJ, Best L, Gangi L, Munroe D, Muegge K. Lsh, an epigenetic guardian of repetitive elements. Nucleic Acids Research. 32: 5019-28. PMID 15448183 DOI: 10.1093/Nar/Gkh821 |
0.075 |
|
| 2016 |
Kader T, Goode DL, Wong SQ, Connaughton J, Rowley SM, Devereux L, Byrne D, Fox SB, Mir Arnau G, Tothill RW, Campbell IG, Gorringe KL. Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue. Genome Medicine. 8: 121. PMID 27846907 DOI: 10.1186/s13073-016-0375-z |
0.071 |
|
| 2005 |
Khan A, Benboubetra M, Sayyed PZ, Ng KW, Fox S, Beck G, Benter IF, Akhtar S. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. Journal of Drug Targeting. 12: 393-404. PMID 15545089 DOI: 10.1080/10611860400003858 |
0.071 |
|
| 2019 |
Kannan S, Fox SJ, Verma CS. Exploring gatekeeper mutations in EGFR through computer simulations. Journal of Chemical Information and Modeling. PMID 31099565 DOI: 10.1021/acs.jcim.9b00361 |
0.071 |
|
| 2007 |
Hiebert CW, Thomas JB, Somers DJ, McCallum BD, Fox SL. Microsatellite mapping of adult-plant leaf rust resistance gene Lr22a in wheat. Tag. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik. 115: 877-84. PMID 17646964 DOI: 10.1007/s00122-007-0604-3 |
0.07 |
|
| 2019 |
Burgess J, Bolderson E, Adams M, Zhang S, Fox S, Wright G, Young R, Solomon B, Gray S, Richard D, O’Byrne K. Chloropyramine increases NSCLC sensitivity to cisplatin in a SASH1 dependent manner Lung Cancer. 127: S1-S2. DOI: 10.1016/s0169-5002(19)30046-7 |
0.07 |
|
| 2018 |
Lee B, Tran B, Hsu AL, Taylor GR, Fox SB, Fellowes A, Marquis R, Mooi J, Desai J, Doig K, Ekert P, Gaff C, Herath D, Hamilton A, James P, et al. Exploring the Feasibility and Utility of Exome-scale Tumour Sequencing in a Clinical Setting. Internal Medicine Journal. PMID 29607586 DOI: 10.1111/Imj.13806 |
0.069 |
|
| 2020 |
Fox S, Goswami C, Holden M, Connolly JPR, Mordue J, O'Boyle N, Roe A, Connor M, Leanord A, Evans TJ. A highly conserved complete accessory Escherichia coli type III secretion system 2 is widespread in bloodstream isolates of the ST69 lineage. Scientific Reports. 10: 4135. PMID 32139768 DOI: 10.1038/s41598-020-61026-x |
0.068 |
|
| 2019 |
Pradhan M, Nguyen MN, Kannan S, Fox SJ, Kwoh CK, Lane DP, Verma CS. Characterization of hydration properties in structural ensemble of biomolecules. Journal of Chemical Information and Modeling. PMID 31140800 DOI: 10.1021/Acs.Jcim.8B00453 |
0.068 |
|
| 2011 |
Meyer TE, Fox SD, Issaq HJ, Xu X, Chu LW, Veenstra TD, Hsing AW. A reproducible and high-throughput HPLC/MS method to separate sarcosine from α- and β-alanine and to quantify sarcosine in human serum and urine. Analytical Chemistry. 83: 5735-40. PMID 21635006 DOI: 10.1021/ac201003r |
0.067 |
|
| 2004 |
Fox SR, Patel UA, Yap MG, Wang DI. Maximizing interferon-gamma production by Chinese hamster ovary cells through temperature shift optimization: experimental and modeling. Biotechnology and Bioengineering. 85: 177-84. PMID 14705000 DOI: 10.1002/bit.10861 |
0.067 |
|
| 2022 |
Doig KD, Love CG, Conway T, Seleznev A, Ma D, Fellowes A, Blombery P, Fox SB. Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. Bmc Medical Genomics. 15: 70. PMID 35346197 DOI: 10.1186/s12920-022-01214-y |
0.066 |
|
| 2017 |
Venkatesh M, Amutha Barathi V, Goh ETL, Anggara R, Fazil MHUT, Ng AJY, Harini S, Aung TT, Fox SJ, Liu S, Yang L, Barkham TMS, Loh XJ, Verma NK, Beuerman RW, et al. Antimicrobial Activity and Cell Selectivity of Synthetic and Biosynthetic Cationic Polymers. Antimicrobial Agents and Chemotherapy. PMID 28784676 DOI: 10.1128/AAC.00469-17 |
0.065 |
|
| 2005 |
Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, ... ... Fox SD, et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. The Journal of Clinical Investigation. 115: 2139-48. PMID 16025158 DOI: 10.1172/JCI23196 |
0.065 |
|
| 2021 |
Goswami C, Fox S, Holden M, Leanord A, Evans TJ. Genomic Analysis of Global Strains Reveals Distinct Lineages With Differing Virulence and Antibiotic Resistance Gene Content. Frontiers in Microbiology. 12: 795173. PMID 34925305 DOI: 10.3389/fmicb.2021.795173 |
0.065 |
|
| 2021 |
Parthibane V, Lin J, Acharya D, Abimannan T, Srideshikan SM, Klarmann K, Yang A, Soheilian F, Nagashima K, Fox SD, Andresson T, Tessarollo L, Keller JR, Acharya U, Acharya JK. SSSPTA is essential for serine palmitoyltransferase function during development and hematopoiesis. The Journal of Biological Chemistry. 100491. PMID 33662400 DOI: 10.1016/j.jbc.2021.100491 |
0.064 |
|
| 2021 |
Fox S. Multiscale Free Energy Analysis of Human Ecosystem Engineering. Entropy (Basel, Switzerland). 23. PMID 33810573 DOI: 10.3390/e23040396 |
0.064 |
|
| 2017 |
Sinclair WR, Arango D, Shrimp JH, Zengeya TT, Thomas JM, Montgomery DC, Fox SD, Andresson T, Oberdoerffer S, Meier JL. Profiling Cytidine Acetylation with Specific Affinity and Reactivity. Acs Chemical Biology. PMID 29039931 DOI: 10.1021/Acschembio.7B00734 |
0.063 |
|
| 2009 |
Li S, Zhang Y, Wang S, Yang J, Araneta MF, Farris A, Johnson C, Fox S, Innis R, Shen J. In vivo 13C magnetic resonance spectroscopy of human brain on a clinical 3 T scanner using [2-13C]glucose infusion and low-power stochastic decoupling Magnetic Resonance in Medicine. 62: 565-573. PMID 19526500 DOI: 10.1002/mrm.22044 |
0.063 |
|
| 2019 |
Choi D, Sonkaria S, Fox SJ, Poudel S, Kim SY, Kang S, Kim S, Verma C, Ahn SH, Lee CS, Khare V. Quantum scale biomimicry of low dimensional growth: An unusual complex amorphous precursor route to TiO band confinement by shape adaptive biopolymer-like flexibility for energy applications. Scientific Reports. 9: 18721. PMID 31822722 DOI: 10.1038/s41598-019-55103-z |
0.062 |
|
| 2014 |
Wong SQ, Li J, Tan AY, Vedururu R, Pang JM, Do H, Ellul J, Doig K, Bell A, MacArthur GA, Fox SB, Thomas DM, Fellowes A, Parisot JP, Dobrovic A, et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. Bmc Medical Genomics. 7: 23. PMID 24885028 DOI: 10.1186/1755-8794-7-23 |
0.062 |
|
| 2019 |
Markham JF, Yerneni S, Ryland GL, Leong HS, Fellowes A, Thompson ER, De Silva W, Kumar A, Lupat R, Li J, Ellul J, Fox S, Dickinson M, Papenfuss AT, Blombery P. CNspector: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. Scientific Reports. 9: 6426. PMID 31015508 DOI: 10.1038/s41598-019-42858-8 |
0.061 |
|
| 2018 |
Arango D, Sturgill D, Alhusaini N, Dillman AA, Sweet TJ, Hanson G, Hosogane M, Sinclair WR, Nanan KK, Mandler MD, Fox SD, Zengeya TT, Andresson T, Meier JL, Coller J, et al. Acetylation of Cytidine in mRNA Promotes Translation Efficiency. Cell. PMID 30449621 DOI: 10.1016/J.Cell.2018.10.030 |
0.06 |
|
| 2020 |
Goswami C, Fox S, Holden MTG, Connor M, Leanord A, Evans TJ. Origin, maintenance and spread of antibiotic resistance genes within plasmids and chromosomes of bloodstream isolates of . Microbial Genomics. PMID 32160146 DOI: 10.1099/mgen.0.000353 |
0.059 |
|
| 2010 |
Takano EA, Mikeska T, Dobrovic A, Byrne DJ, Fox SB. A multiplex endpoint RT-PCR assay for quality assessment of RNA extracted from formalin-fixed paraffin-embedded tissues. Bmc Biotechnology. 10: 89. PMID 21162754 DOI: 10.1186/1472-6750-10-89 |
0.059 |
|
| 2021 |
Lightfoot N, Kirkova Y, Fox S, Alan S. Overcoming Challenges to Surrogate Decision Making for Young Adults at the End of Life. The American Journal of Hospice & Palliative Care. 10499091211001007. PMID 33715423 DOI: 10.1177/10499091211001007 |
0.058 |
|
| 2018 |
Thomas JM, Briney CA, Nance KD, Lopez JE, Thorpe AL, Fox SD, Bortolin-Cavaille ML, Sas-Chen A, Arango D, Oberdoerffer S, Cavaille J, Andresson T, Meier JL. A Chemical Signature for Cytidine Acetylation in RNA. Journal of the American Chemical Society. PMID 30252461 DOI: 10.1021/Jacs.8B06636 |
0.057 |
|
| 2015 |
Rogers TM, Fox SB. In Response. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: e85. PMID 26200294 DOI: 10.1097/JTO.0000000000000604 |
0.055 |
|
| 2023 |
Ovadia YS, Dror I, Liberty G, Gavra H, Anteby EY, Fox S, Berkowitz B, Zohav E. Amniotic fluid rubidium concentration association with newborn birthweight: A maternal-neonatal pilot study. American Journal of Obstetrics & Gynecology Mfm. 101149. PMID 37660761 DOI: 10.1016/j.ajogmf.2023.101149 |
0.055 |
|
| 2021 |
Fox S. Future-Proofing Startups: Stress Management Principles Based on Adaptive Calibration Model and Active Inference Theory. Entropy (Basel, Switzerland). 23. PMID 34573780 DOI: 10.3390/e23091155 |
0.052 |
|
| 2022 |
Link CN, Thalalla Gamage S, Gallimore D, Kopajtich R, Evans C, Nance S, Fox SD, Andresson T, Chari R, Ivanic J, Prokisch H, Meier JL. Protonation-Dependent Sequencing of 5-Formylcytidine in RNA. Biochemistry. 61: 535-544. PMID 35285626 DOI: 10.1021/acs.biochem.1c00761 |
0.051 |
|
| 2019 |
Levy MJ, Montgomery DC, Sardiu ME, Montano JL, Bergholtz SE, Nance KD, Thorpe AL, Fox SD, Lin Q, Andresson T, Florens L, Washburn MP, Meier JL. A Systems Chemoproteomic Analysis of Acyl-CoA/Protein Interaction Networks. Cell Chemical Biology. PMID 31836350 DOI: 10.1016/J.Chembiol.2019.11.011 |
0.051 |
|
| 2005 |
Somers DJ, Thomas J, Depauw R, Fox S, Humphreys G, Fedak G. Assembling complex genotypes to resist Fusarium in wheat (Triticum aestivum L.). Tag. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik. 111: 1623-31. PMID 16179996 DOI: 10.1007/s00122-005-0094-0 |
0.05 |
|
| Hide low-probability matches. |